ASHLEY ANH VO, PHARM.D CURRICULUM VITAE
PERSONAL HISTORY Business Address: Cedars-Sinai Medical Center Comprehensive Transplant Center 8900 Beverly Blvd. Los Angeles, CA 90048
Business Telephone: (310) 423-4021
Business Fax: (310) 423-6369
Internet Address: [email protected]
EDUCATION College University of California, Irvine Irvine, CA Bachelor of Biological Sciences 1984-1988
Pharmacy School University of Southern California Los Angeles, CA Doctor of Pharmacy 1988-1992
Internship UCLA Medical Center December 1988-May 1992
General Residency Cedars-Sinai Medical Center Los Angeles, CA 1992-1993
Specialty Residency Administrative Residency Cedars-Sinai Medical Center Los Angeles, CA 1993-1994
LICENSURE California #45557, 1992 Nevada #11412, 1992 PROFESSIONAL EXPERIENCE Administrative Director, Transplant Immunotherapy Program 6/2004 -Comprehensive Transplant Center Cedars-Sinai Medical Center
Clinical Research Coordinator 6/1997 - Center for Kidney & Liver Diseases and Transplantation Cedars-Sinai Medical Center
Preceptor for Transplant Rotation 9/1997 - Department of Pharmacy Cedars-Sinai Medical Center
Heart/Lung/Kidney Transplant Pharmacist 7/1996 - Center for Kidney & Liver Diseases and Transplantation Cedars-Sinai Medical Center
Liver Transplant Pharmacist 9/1995-6/1996 Center for Kidney & Liver Diseases and Transplantation Cedars-Sinai Medical Center
Antibiotic Use Review Pharmacist 3/1995-9/1995 Cedars-Sinai Medical Center
DEPARTMENT / DIVISION COMMITTEES Heart & Kidney Transplant Patient Selection Committee 1996- CTC Quality Improvement Committee 2007-
COMMUNITY SERVICES Southern California Association for Transplant Pharmacy 2001- Southern California Society of Hospital Pharmacy 1992- Asian Transplantation Awareness of Southern California 1999-2001
PROFESSIONAL MEMBERSHIP Transplantation Society 2009- American Clinical College of Pharmacy 2002 to 2006 American Society of Transplantation 1997- California Society of Hospital Pharmacy 1991 to 1996 American Society of Hospital Pharmacists 1991 to 1996
ACADEMIC APPOINTMENT Assistant Clinical Professor of Pediatrics David Geffen School of Medicine at UCLA 7/2005 - Page 2 - Updated –5/26/17 Associate Clinical Professor of Pediatrics (Step I) David Geffen School of Medicine at UCLA 7/2009
Associate Clinical Professor of Pediatrics (Step III) David Geffen School of Medicine at UCLA 7/2011
Clinical Professor of Pediatrics (Step I) David Geffen School of Medicine at UCLA 7/2013
Clinical Professor of Pediatrics (Step II) David Geffen School of Medicine at UCLA 7/2016
Adjunct Assistant Professor of Pharmacy Practice 4/2012 USC School of Pharmacy
HONORS AND AWARDS Visiting Professor, Toronto University Hospital, Toronto, Canada 11/2007 Reviewer, American Journal of Kidney Diseases 7/2008 Apples for Preceptor Award from UCSF School of Pharmacy 3/2009 & 3/2010 New Key Opinion Leader, Transplantation Society 7/2009 Reviewer, American Journal of Transplantation 12/2010 & 5/2011 Co-Chair: HLA Incompatible Kidney Transplantation, ATC 2011 5/2011 Co-Chair: Kidney Immunosuppression: Desensitization, ATC 2012 6/ 2012 Co-Chair: Non-Complement Fixing and Non-HLA Antibodies and 7/2014 Kidney-Allograft Survival, WTC 2014 Co-Chair: Kidney AMR: Making the Diagnosis, ATC 2016 6/2016 Reviewer, Progress in Transplantation 12/2012 & 12/2015 Reviewer, Dove Press 12/2012 & 11/2015 Reviewer, American Journal of Transplantation 2013 & 2015 Reviewer, Human Immunology 3/2013& 12/2015 Reviewer, Nephron Clinical Practice 2/2015 AST Clinician of Distinction Award 7/2014 ATC 2016 Abstract Reviewer 12/2015 Reviewer, Transplantation 2/2016 & 3/2017 Reviewer, American Journal of Kidney Disease 2/2016 Reviewer, Journal of Virology & AIDS 4/2016 Reviewer, Journal of Immunology 11/2016 & 2/2017 Reviewer, PLOS One 12/2016 Fellow, American Society of Transplantation 6/2016
RESEARCH GRANTS
- Page 3 - Updated –5/26/17 1. Research Coordinator, NIH Grant: Evaluation of Intravenous Gammaglobulin as an Agent for the Treatment of Allograft Rejection in Renal Allograft Recipients. (Completed). 1996-1997
2. Research Coordinator, NIH Grant: Evaluation of Gammaglobulin as an Agent to Lower Allosensitization and Improve Allograft Survival in Highly Sensitized ESRD Patients. (Completed). 1997-2002
3. Co-Principal Investigators, Fujisawa sponsor: Prograf as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure. (Completed). 1998-2003
4. Co-Principal Investigator, Roche sponsor Multicenter Study: An Open Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Zenapax in Combination with CellCept, Corticosteroids and Standard or Reduced Dose Prograf for the Prevention of Acute Rejection in Primary Renal Allograft Recipients. (Completed). 1999-2000
5. Co-Principal Investigators, Abbott Inc.: A Randomized, Open-Label Preference Study of Gengraf Compared to Neoral in Stable Solid-Organ Transplant Subjects. (Completed). 1999- 2000
6. Co-Principal Investigators, Wyeth Sponsored Study: A Prospective Study of Induction and Maintenance Immunosuppression with Rapamycin, Daclizumab and Corticosteroids and Low Dose Tacrolimus for Cadaveric, Living Related or Living Unrelated Kidney Transplants. (Completed). 2000-2001
7. Research Coordinator, National Institute of Health: Evaluation of Immune Globulin Intravenous, Human Manufactured Using a New Chromatographic Method (IGIV-C), 10%, As An Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross March Positive Living Donor Kidney Allograft Recipients. (Completed). 2003-2006 $950,000
8. Co-Principal Investigators, Novartis Pharmaceuticals, Inc. Grant: A Six Multi-Center Open Labeled Study to Compare the Impact of Neoral C-2 Monitoring on Safety and Efficacy Outcomes in De Novo Kidney Transplant Recipients. (Completed). 2001-2003
9. Co-Principal Investigators, Novartis Pharmaceuticals, Inc. Grant: A One Year Multicenter, Randomized, Open Label, Parallel Group Study of the Safety, Tolerability and Efficacy of Two Doses (1.5 and 3mg/day) of Certican (RAD001) with Steroids and Optimized Administration of Neoral in De Novo Renal Transplant Recipients. (Completed). 2001-2003
10. Co-Principal Investigators, National Institute of Health: A Randomized, Controlled Clinical Trial of the Effect of a High Dose Combination of Folic Acid, Vitamin B6 and Vitamin B12, on Arteriosclerotic Cardiovascular Disease Outcomes in Chronic, Stable Renal Transplant Recipients. (Active). 2000-2007
- Page 4 - Updated –5/26/17 11. Co-Principal Investigators: Fujisawa Healthcare Inc. A Phase III, Randomized, Open- Label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in de novo Kidney Transplant Recipients. (Active). 2003-2007.
12. Co-Principal Investigators: Novartis Sponsor Multicenter Study: An Extension to a One Year Multicenter, Randomized, Open Label, Parallel Group Study of the Safety, Tolerability, and Efficacy of Two Doses (1.5 and 3 mg/day) of Certican™ (RAD001) with Steroids and Optimized Administration of Neoral® in De Novo Renal Transplant Recipients. (Completed). 2003-2006
13. Co-Principal Investigators: Roche Sponsor Single Center Pilot Study: Oral Valganciclovir as a Treatment for Active CMV Infection in Solid Organ Transplant. (Completed). 2004-2006
14. Co-Principal Investigators: Novartis Sponsor Multicenter Study: Novartis Protocol CRAD001AUS09- A Prospective multicenter, open label, randomized study of the safety, tolerability and efficacy of Certican (RAD001) with Simulect, corticosteroids and lower levels versus higher levels of tacrolimus in de novo renal transplant recipients. (Completed). 2004- 2006
15. Co-Principal Investigators: Genentech Sponsor Single Center Pilot Study: A Phase I/II Trial to Investigate the Safety and Efficacy of Rituxan and Intravenuous Gammaglobulin (IVIG) as Agents to Desensitize Highly-HLA Sensitized Dialysis Patients Awaiting Kidney Transplantation. (Completed). 2005-2008
16. Co-Principal Investigators: Roche Sponsor Multicenter Study: An open label, prospective, randomized, controlled, multi-center study assessing fixed dose vs. concentration controlled CellCept regimens for patients following a single organ renal transplantation in combination with full dose and reduced dose calcineurin inhibitors. #TDM ML17225/01265. (Completed). 2005-2007
17. Co-Principal Investigators: Novartis Sponsor Multicenter Study: CER080AUS02: MyTIME – A three-month, open-label, two cohort study to investigate the safety and tolerability of Myfortic in combination with Neoral or Tacrolimus in renal transplant recipients with GI intolerance. (Completed). 2005-2006
18. Co Principal Investigators: Pfizer Sponsor Multicenter Study: Protocol A 3921009: A 6- month, Phase 2, Multicenter, Randomized, Open-Label, Comparative Study of Two Dose Levels of CP -690,550 Administered Concomitantly with IL-2 Receptor Antagonist Induction Therapy, Mycophenolate Mofetil and Corticosteroids versus a Tacrolimus-based Immunosuppressive Regimen for the Prevention of Allograft Rejection in De Novo Renal Allograft Recipients. (Completed). 2005-2009
19. Co-Principal Investigators: Novartis Sponsor Multicenter Study: ERL080A2409: A Prospective Open Label Study of The Safety, Tolerability and Efficacy of Myfortic® with - Page 5 - Updated –5/26/17 Simulect, Corticosteroids and Lower vs. Higher Levels of Tacrolimus in De Novo Renal Transplant Recipients – A Six Month Study of Kidney Transplant Recipients Evaluating the Safety, Tolerability, and Efficacy of Myfortic (ERL080) with Simulect, Corticosteroids, and Low vs. High Doses of Tacrolimus. (Completed). 2006-2007
20. Co Principal Investigators: Bristol-Myers Squibb Sponsor Multicenter Study: Belatacept Evaluation of Nephroprotection and Efficacy as First –Line Immunosuppression Trial. (Completed). 2006-2012
21. Co Principal Investigators: Novartis Sponsor Multicenter Study: CERL080A-US51: A 4- week, multicenter, double-blind, randomized, parallel group study to compare the gastrointestinal (GI) safety and tolerability of myfortic® and MMF (CellCept®) when administered in combination with calcineurin inhibitors (CNI) in renal transplant recipients experiencing gastrointestinal intolerance. (Completed) 2007-2008
22. Co Principal Investigators: Pfizer Sponsor Multicenter Study: A3921030: A Phase 2 randomized, multicenter, active comparator-controlled trial to evaluate the safety and efficacy of coadministration of CP-690,550 and mycophenolate mofetil/mycophenolate sodium in de novo kidney allograft recipients. (Completed) 2008-2014
23. Co-Principal Investigators: Genentech. “Comparison of Immune Globulin Intravenous (Human), 10% (IVIG), plus Rituximab vs. IVIG 10% + Placebo (0.1% albumin) as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation.” (Completed). 2010- 2012. NCT01178216 $1,005,853.
24. Co-Principal Investigators: Novartis. “A 12 Month, Multi-Center, Randomized, Open- Label Noninferiority Study Comparing the Safety and Efficacy of Concentration-Controlled Everolimus with Low Dose Tacrolimus to CellCept® (Mycophenolate Mofetil) with Standard Dose Tacrolimus in De Novo Renal Transplant Recipients.” (Completed). 2010-2012
25. Co-Principal Investigators: Quark. “Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation.” (Completed). 2010-2014
26. Co-Principal Investigators: CSL-Behring: Study/Protocol Title: “A Phase I/II Trial to Evaluate the Safety & Efficacy of Berinert® (C1 Inhibitor) Therapy to Prevent Complement- Dependent, Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.” (Completed). 2011-2013. NCT01134510 $320,000
27. Co-Principal Investigators: Genentech. “A Phase I/II Trial of Tocilizumab + Intravenous Immunoglobulin (IVIG) as Agents to Reduce Donor-Specific Anti-HLA Antibodies (DSA) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Kidney Transplantation.” (Completed). 2012-2014. NCT01594424
- Page 6 - Updated –5/26/17 28. Co-Principal Investigators: Genentech. “Comparison of Immune Globulin Intravenous (Human), 10% (IVIG), plus Rituximab as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation.” (Completed). 2013. NCT01178216
29. Co-Principal Investigators: Novartis Sponsored Investigator Initiated Phase I/II Clinical Trial: “A Phase I/II Trial to Evaluate Safety and Tolerability of Zortress (Everolimus) for the Prevention of BK and CMV Viremia in HLA Sensitized Kidney Transplant Recipients.” (Completed). 2013-2015 $234,811
30. Co-Principal Investigators: Bristol Myers-Squibb. “Evaluating Nulojix Long-term Safety in Kidney Transplant: ENLIST Registry”. (Active). 2013
31. Co-Principal Investigators: CSL-Behring sponsored Investigator Initiated Study/Protocol Title: “C1 INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI (C1INHDGF)”. (Active). 2014. NCT 02134314
32. Co-Principal Investigators: Bristol Myers-Squibb. Evaluation of the Benefits in Maintenance Renal Transplant Recipients Following Conversion to Nulojix (belatacept)-based Immunosuppression. (Active). 2015 $160,259.10
33. NIH Grant (Collaboration with UCSF): Co-Principal Investigators: Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts U01 AI113362-01: T-regulatory Cells (TASK) and Tocilizumab (TRAIL). FDA IND application pending.
34. Co-Principal Investigators: Novartis Sponsored. A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen. (TRANSFORM STUDY). (Active). 2015
35. Co-Principal Investigators: CareDx, Inc. Circulating Donor-Derived Cell-free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients (DART). (Active). 2015
36. Co-Principal Investigators: Investigator Initiated / Hansa Medical. A Phase I/II Trial to Evaluate the Safety and Tolerability of IdeS (IgG endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly HLA Sensitized Patients; NCT 02475551. (Active). 2015
37. Co-Principal Investigators: Genenetech Sponsored. A Phase Ib, Single- and Multiple- Dose, Open Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Obinituzumab in Adults With ESRD and Hypersensitization Awaiting Renal Transplantation. (Active). 2015
- Page 7 - Updated –5/26/17 38. Co-Principal Investigators: Hansa Medical Sponsored. A Phase II Study to Evaluate the Efficacy of IdeS (IgG endopeptidase) to Desensitize Transplant Patients with a Positive Crossmatch Test. (Active). 2016
39. Co-Principal Investigators: Novartis Sponsored. Open-label, parallel-group, drug-drug interaction study in end-stage renal disease patients awaiting kidney transplant to investigate the potential effect of IVIG treatment on the pharmacokinetics and pharmacodynamics of LFG316. (Active). 2016
40. Co-Principal Investigators: Astellas sponsored Investigator Study: A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended -Release (Astagraf XL) in HLA Sensitized Kidney Transplant Recipients. (Active). 2017
PEER REVIEWED RESEARCH PAPERS 1. Noha R. Barsoum, Suphamai Bunnapradist, Asha Moudgil, Mieko Toyoda, Ashley Vo and Stanley C. Jordan. Treatment of Parvovirus B-19 (PV B-19) Infection Allows for Successful Kidney Transplantation Without Disease Recurrence. American Journal of Transplantation 2002; 2:425-428.
2. Bunnapradist S. Vo A. Toyoda M. Alsabeh R. Lockhart C. Puliyanda D. Jordan SC. Post transplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation. Transplantation. 74(11):1648-51, 2002 Dec 15
3. Jordan, SC, Vo, A, Bunnapradist, S, Toyoda, M, and Kamil, E. Treatment of active CMV infection with oral ganciclovir in renal allograft recipients: Monitoring efficacy with quantitative CMV-PCR. Am. J. of Transplantation. 2002; 2: 671-3.
4. Bunnapradist S, Hristea I, Vo A, Toyoda M, Alsabeh R, Lockhart C, Puliyanda D, Jordan SC. An Unusual Presentation of Post-Transplant Lymphoma. Review Series; Oncology: 19-21; April 2003.
5. Jordan, SC, Vo, A. , Bunnapradist, S., Toyoda, M., Peng, A., Puliyanda, D., Kamil, E. Intravenous immune globulin treatment inhibits cross match positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76:631-636.
6. Jordan SC, Tyan, D., Stablein, D., McIntosh, M., and Vo, A. Evaluation of IVIG as an agent to lower allosensitization and improve transplantation in highly-sensitized adult patients with ESRD. Transplantation Reviews 17: 2003; S34.
7. Jordan SC, Vo, A., Nast, C, and Tyan, D. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl. 2003: 193-8. - Page 8 - Updated –5/26/17 8. Vo, A., SC. Jordan. IVIG Therapy: an Emerging Role in Organ Transplantation. US Pharmacist, HS-36; March 2004. 154.
9. Jordan, SC, Tyan, D., Stablein, D., McIntosh, M., Rose, S., Vo, A., Toyoda, M., Davis, C., Shapiro, R., Adey, D., Milliner, D., Graff, R., Steiner, R., Light, J., Ciancio, G., and Shanney, S. Evaluation of intravenous immunoglobulin (IVIG) as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end- stage renal disease: Report of the NIH IG02 Trial. J Am Soc Nephrol 15: 3256-62, 2004.
10. Ingle, G., Moudgil, A., Vo, A., and Jordan, SC. Cyclosporine sparing effects of daclizumab and mycophenolate mofetil in renal allograft recipients. Am. J. Health- Systems Pharmacy. Feb 2005; 62:391-396.
11. Jordan SC, Vo AA, Toyoda M, Tyan D, Nast CC. Post-transplant therapy with high dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatric Transplantation Apr 2005; 9(2):155-161.
12. Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M. Current approaches to treatment of antibody mediated rejection. Pediatric Transplantation Jun 2005: 9(3); 408-15.
13. Toyoda, M., Puliyanda, D., Amet, N., Baden, L., Cam, V., Radha, R., Pao, A., Vo, A., Bunnapradist, S., Moudgil, A., Jordan, SC. Co-infection of Polyoma BK Virus and CMV in Renal Transplant Recipient. Transplantation Jul 27, 2005; 80(2): 198-205.
14. Puliyanda DP, Silverman NS, Lehman D, Vo A, Bunnapradist S, Radha RK, Toyoda M, Jordan SC. Successful use of oral ganciclovir for the treatment of intrauterine CMV infection in a renal allograft recipient. Infectious Disease 2005: 7(2):71-4.
15. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients. Am J Transplant. Mar 2006; 6(3):459-66.
16. Vo, A., Jordan, S., Sacher, R. IGIV Therapy: Clinical and Pharmaceutical Considerations for 2006. Symposium News Reporter. February 2006
17. Vo, A., Cam, V., Toyoda, M., Puliyanda, D., Lukovsky, M., Bunnapradist, M., Peng, A., and Jordan, SC. Safety and adverse event profiles of IVIG products used for immunomodulation: A single center experience. Clin J. Am. Soc Nephrol. Jul 2006; 1: 844-852.
18. Vo, A., M. Toyoda, A. Peng, S. Bunnapradist, M. Lukovsky, and S. Jordan. Effect of Induction Therapy Protocols on Transplant Outcomes in Crossmatch Positive Renal Allograft Recipients Desensitized with IVIG. Am J Transplant. October 2006; 6(10): 2384-2390.
- Page 9 - Updated –5/26/17 19. Peng, A, Vo, A, and Jordan, S,. Transplantation of the Highly Human Leukocyte Antigen-Sensitized Patient: Long-Term Outcomes and Future Directions. Transplantation Reviews 20 (2006) 146-165.
20. Jordan SC, Toyoda M., Vo A, Tyan D. Desensitization Therapy with Intravenous Gammaglobulin (IVIG): Applications in Solid Organ Transplantation. Transactions of the American Clinical and Climatological Association. 2006; 117: 199–211.
21. Hristea I, Bunnapradist S, Peng A, Puliyanda D, Vo A, Jordan SC. The onset of rapidly progressive neurologic deterioration after a brief gastrointestinal illness in a kidney transplant recipient. Transplant Infectious Diseases 2007: 9: 142-147.
22. Tom Yang, Cynthia C. Nast, Ashley Vo, and Stanley C. Jordan. Rapid remission of steroid and mycophenolate mofetil (mmf)—resistant minimal change nephritic syndrome after rituximab therapy. Nephrol Dial Transplant. 2007.
23. Vo, A., Weschler, EA., Wang, J., Peng, A., Toyoda, M., Lukovsky, M., Reinsmoen, N., and Jordan, SC. Analysis of Subcutaneous (SQ) Alemtuzumab Induction Therapy in Highly Sensitized Patients Desensitized with IVIG and Rituximab. American Journal of Transplantation 2008; 8:144-9.
24. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. Rituximab and intravenous immune globulin for desensitization during renal transplantation. The New England Journal of Medicine; 2008 Jul 17; 359(3):242-51.
25. Eric Wechsler, Tom Yang, Stanley C. Jordan, Ashley Vo, and Cynthia C. Nast. Anti- glomerular basement membrane disease in an HIV-infected patient. Nature Clinical Practice Nephrology 2008;4:167-171.
26. Ashley A. Vo, Marina Lukovsky, Mieko Toyoda, Jennifer Wang, Nancy Reinsmoen, Chih-Hung Lai, Alice Peng, Rafael Villicana, and Stanley Jordan. Rituximab and Immune Globulin for Desensitization during renal transplantation. The New England Journal of Medicine 2008;359 (16): 1731-32.
27. Reinsmoen N, Lai CH, Vo A, Cao K, Ong G, Naim M, Wang Q, and Jordan SC. Acceptable Donor-Specific Antibody Levels Allowing for Successful Deceased and Living Donor Kidney Transplantation After Desensitization Therapy. Transplantation 2008; 86:820-825.
28. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation July 15, 2009: Vol 88: 1-6.
29. Joseph Kahwaji, Chris Tong, Stanley C. Jordan, and Ashley A. Vo. Rituximab: An Emerging Therapeutic Agent for Kidney Transplantation. Transplant Research and Risk Management. 2009: 15-29.
- Page 10 - Updated –5/26/17 30. Kahwaji J, Barker E, Pepkowitz S, Klapper E, Villicana R, Peng A, Chang R, Jordan SC, Vo AA.. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Soc Nephrol.2009 Dec; 4(12):1993-7.
31. Sivakumaran P, Vo AA, Villicana R, Peng A, Jordan SC, Pepkowitz SH, Klapper EB. Therapeutic plasma exchange for desensitization prior to transplantation in ABO- incompatible renal allografts. J Clin Apher. 2009. 24(4): 155-60.
32. Jordan SC, Peng A, Vo AA. Therapeutic strategies in management of the highly HLA- sensitized and ABO-incompatible transplant recipients. Contrib Nephrol. 2009;162:13- 26.
33. Toyoda M, Pao A, Vo A, Lukovsky M, Radha R, Sado T, Petrosyan A, Ge S, Mirocha J, and Jordan SC. Immune cell production of IFN- after allo-antigen exposure measures allosensitization and predicts antibody-mediated rejection in highly-HLA sensitized patients. Transplantation Immunology 2010;3-4:121-127.
34. Jordan SC, Peng A, Reinsmoen N, Lai C-H, Cao K, Villicana R, Toyoda M, Kahwaji J, and Vo A. Advances in the diagnosis and management of antibody-mediated rejection. Pediatric Nephrology 2010;10: 2035-2048.
35. Toyoda, M., Pao, A., Vo, A., Lukovsky, M., Radha, R., Sadu, T., Ge, S., Reinsmoen, N., Chai, N., Baden, L., Petrosyan, A., Skinner, E., Mirocha, J., and Jordan, S. Intracellular IFNγ Production in CD3 Negative Cells Exposed to Allo-Antigens is an Indicator of Prior Sensitization. Transplant Immunology.2010 (22):121-127.
36. Jordan SC, Reinsmoen N, Peng A, Lai CH, Cao K, Villicana R, Toyoda M, Kahwaji J, Vo AA. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol. 2010 Oct; 25(10):2035-45; quiz 2045-8. Published online: January 2010.
37. Vo AA, Peng A., Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-102.
38. Toyoda, M., Ge, S., Pao, Vo, A., Deer, N., Aguiluz, A., Karasyov, A., and Jordan, S. Cellular Allo Reactivity Against Paternal HLA Antigens in Normal Multiparous Females as Detected by Intracellular Cytokine Flow Cytometry Remains Elevated Over Years Despite Diminution of Anti-HLA Antibody Levels. Transplant Immunology. 2010; (23):133-140.
39. Jordan SC, Reinsmoen N and Vo AA. Intravenous immunoglobulin and rituximab for desensitization. Transplantation 2010; 90: 932-3.
- Page 11 - Updated –5/26/17 40. Kahwaji J, Vo AA, Jordan SC. ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation? Expert Rev Clin Immunol. 2010 Nov; 6(6):893-900.
41. Ge S, Pao A, Vo A, Deer N, Karasyov A, Petrosyan A, Kahwaji J, Lukovsky M, Chai NN, Aguiluz A, Mirocha J, Jordan SC, Toyoda M. Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. Transpl Immunol. 2011 Apr 15; 24(3):142-8. Epub 2010 Nov 28.
42. Reinsmoen NL, Lai CH, Heidecke H, Haas M, Cao K, Ong G, Naim M, Wang Q, Mirocha J, Kahwaji J, Vo AA, Jordan SC, Dragun D. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation. 2010 Dec 27; 90(12):1473-7.
43. Sinha A, Nast CC, Hristea I, Vo AA, Jordan SC. Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy. Clin Exp Nephrol. 2011 Feb; 15(1):164-70.
44. Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol. 2011 May; 7(3):341-8.
45. Lai CH, Cao K, Ong G, Naim M, Wang Q, Mirocha J, Vo A, Jordan SC, Reinsmoen NL. Antibody Testing Strategies for Deceased Donor Kidney Transplantation After Immunomodulatory Therapy. Transplantation. 2011 Jul 15; 92(1):48-53.
46. Jordan SC, Kahwaji J, Toyoda M, Vo A. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr Opin Organ Transplant. 2011 Aug; 16(4):416-24.
47. Kahwaji J, Sinha A, Toyoda M, Ge S, Reinsmoen N, Cao K, Lai CH, Villicana R, Peng A, Jordan SC, and Vo A. Infectious Complications in Kidney-Transplant Recipients Desensitized with Rituximab and Intravenous Immunoglobulin. Clinical Journal of the American Society of Nephrology. 2011 Dec 6: (12) 2894-2900.
48. Jordan SC, Toyoda M, Kahwaji J, and Vo A. Clinical aspects of IVIG therapy in solid organ transplant recipients. Am. J. Transplantation 2011; 11:196-202.
49. Jordan SC, Reinsmoen N, Lai C-H, Cao K, Kahwaji J, Peng A, Villicana R and Vo A. Desensitization the broadly sensitized patient awaiting deceased donor kidney transplantation. Transp. Proc. 2012; 44:60.
50. Toyoda M, Ge S, Suviolahti E, Pichurin P, Shin B, Pao A, Vo A, Reinsmoen N, Deer N, Aguiluz A, Karasyov A, and Jordan SC. IFN production by NK cells after alloantigen exposure identifies immunologic memory and risk for antibody mediated rejection post- transplant in highly HLA sensitized patients. Transpl Immunol. 2012 Mar; 26(2-3):107- 12. Epub 2011 Nov 10.
- Page 12 - Updated –5/26/17 51. Jordan SC, Reinsmoen N, Lai C-H, and Vo A. Novel immunotherapeutic approaches to improve rates and outcomes of transplantation in sensitized renal allograft recipients. Discovery Medicine 2012; 13:235-45.
52. Reinsmoen N, Lai C-H, Vo A, and Jordan SC. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discovery Medicine 2012; 13(71):267-73.
53. Jordan SC, Vo AA. Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant. Am J Kidney Dis. 2012 Jun; 59(6):758-60.
54. Vo A, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A, Villicana R, and Jordan SC. Efficacy, outcomes and cost effectiveness of desensitization using IVIG and rituximab. Transplantation 2013; 95(6):852-8.
55. Stanley C. Jordan, Ashley Vo, Chih-Hung Lai, Nancy Reinsmoen. Defining the benefits of desensitization therapy. Transplantation 2013: 95(6): e31-2.
56. Jordan SC, Vo AA. Evolving concepts in desensitization. Clin Transpl. 2013:285-92.
57. Shin BH, Ge S, Mirocha J, Karasyov A, Vo A, Jordan SC, Toyoda M. Regulation of anti- HLA antibody-dependent natural killer cell activation by immunosuppressive agents. Transplantation. 2014 Feb 15; 97(3):294-300.
58. Barbosa D, Kahwaji J, Puliyanda D, Mirocha J, Reinsmoen N, Lai CH, Villicana R, Peng A, Jordan SC, Vo A, Toyoda M. Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab. Transplantation. 2014 Apr 15; 97(7):755-61.
59. Kahwaji J, Najjar R, Kancherla D, Villicana R, Peng A, Jordan S, Vo A, Haas M. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Clin Transplant. 2014 May; 28(5):546-53.
60. Irene K. Kim, Ashley Vo, Stanley C. Jordan. Transplantation in Highly HLA-Sensitized Patients: Challenges and Solutions. Transplantation. 2014; (6):99-107.
61. A. A. Vo and S.C. Jordan. Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy. Clinical and Experimental Immunology. 2014; 178:48-51.
- Page 13 - Updated –5/26/17 62. Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, Ge S, Toyoda M, Kahwaji J, Peng A, Villicana R, Jordan SC. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014 Aug 15; 98(3):312-9.
63. Jordan SC, Vo AA. Donor-specific antibodies in allograft recipients: etiology, impact and therapeutic approaches. Curr Opin Organ Transplant. 2014 Dec; 19(6):591-7.
64. Jordan SC & Vo A. Future directions in desensitization therapy. ASHI Quaterly 2014; 38: 28-31.
65. Ashley A. Vo, Adriana Zeevi, Jua Choi, Kristen Cisneros, Mieko Toyoda, Joseph Kahwaji, Alice Peng, Rafael Villicana, Dechu Puliyanda, Nancy Reinsmoen, Mark Haas, and Stanley C. Jordan. A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients. Transplantation. 2015 Feb; 99(2):299-308.
66. Jordan SC, Choi J, Vo A. Kidney transplantation in highly sensitized patients. Br Med Bull. 2015 Jun;114(1):113-25. Epub 2015 May 1.
67. Ashley A. Vo, Aditi Sinha, Mark Haas, Jua Choi, James Mirocha, Joseph Kahwaji, Alice Peng, Rafael Villicana, and Stanley C. Jordan. Factors Predicting Risk for Antibody- Mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. Transplantation. 2015 Jul; 99(7):1423-30.
68. Ashley A. Vo, Jua Choi, Irene Kim, Sabrina Louie, Kristen Cisneros, Joseph Kahwaji Mieko Toyoda, Shili Ge, Mark Haas, Dechu Puliyanda, Nancy Reinsmoen, Alice Peng, Rafael Villicana, and Stanley C. Jordan. A Phase I/II Trial of the Interleukin-6 Receptor Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. Transplantation. 2015 Nov; 99 (11): 2356-2363.
69. Toyoda M, Thomas D, Ahn G, Kahwaji J, Mirocha J, Chu M, Vo A, Suviolahti E, Ge S and Jordan SC. Polyomavirus-JC Infection and Risk for Progressive Multifocal Leukoencephalopathy in HLA-Sensitized Kidney Transplant Recipients Desensitized with IVIG and Rituximab. Transpl Infect Dis. 2015 Dec;17(6):838-47.
70. Wongsaroj P, Kahwaji J, Vo A, Jordan SC. Modern approaches to incompatible kidney transplantation. World J Nephrol. 2015; 4(3): 354-62.
- Page 14 - Updated –5/26/17 71. Jordan SC, Choi J, Vo A. Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy. 2015; 7(4):377-98.
72. Jordan SC, Choi J, and Vo A. Strategies to improve novel drug development in kidney transplantation through the clinical trials process. Clinical Transplants 2016; 1163-172
73. Kahwaji J, Choi J, Vo A, and Jordan SC. Immunologic and infectious complications in the highly sensitized patients post kidney transplant. Clinical Transplants. 2016; 265-272
74. Stanley C. Jordan, MD1,2,5†, Tomas Lorant, MD6†, Jua Choi, Pharm.D.1,2 Christian Kjellman, PhD12, Lena Winstedt, PhD12, Mats Bengtsson, MD9, Xiaohai Zhang, PhD3, Torsten Eich MD9, Mieko Toyoda, PhD1,5, Britt-Marie Eriksson, MD8, Shili Ge, PhD1,5, Alice Peng, MD1,2, Sofia Järnum PhD12, Kathryn J Wood, DPhil10, Torbjorn Lundgren, MD11, Lars Wennberg, MD11, Lars Bäckman, MD6, Erik Larsson, MD9, Rafael Villicana, MD1,2, Joe Kahwaji, MD1,2, Sabrina Louie, MPH1,2, Alexis Kang, BS1,2, Mark Haas, MD4, PhD, Cynthia Nast, MD4, Ashley Vo, Pharm.D£1,2 and Gunnar Tufveson, MD£6. Initial Experience with The Bacterial Enzyme IdeS (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized Patients. New England J. of Medicine 2016 (submitted)
75. Joseph Kahwaji, Stanley C. Jordan, Reiad Najjar, Patarapha Wongsaroj, Alice Peng, Rafael Villicana, and Ashley Vo. Six-Year Outcomes in Broadly HLA-Sensitized Living Donor Transplant Recipients Desensitized with Intravenous Immunoglobulin and Rituximab. Transplantation International 2016 Aug 16. 1276-1285.
76. Stanley C. Jordan, Jua Choi, Irene Kim, Ashley Vo, Alice Peng, and Joseph Kahwaji. Risk factors associated with the development of histocompatibility leukocyte antigen sensitization. Current Opinion in Organ Transplantation. 2016 Aug;21(4):447-52.
77. SC Jordan, J Choi, J Kahwaji and A Vo. Progress in Desensitization of the Highly HLA Sensitized Patients. Transplantation Proceedings 2016; 48 (3):802-805.
78. SC Jordan, J Choi, and A Vo. Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients. Transplantation Proceedings 2016; 48 (3):806-808.
79. Ge S, Karasyov A, Sinha A, Petrosyan A, Lovato D, Thomas DL, Vo A, Jordan SC, Toyoda M. Cytomegalovirus Immunity after Alemtuzumab Induction in Desensitized Kidney Transplant Patients. Transplantation. 2016 Nov 10. [Epub ahead of print]
- Page 15 - Updated –5/26/17 80. Stanley C. Jordan, Jua Choi, Irene Kim, Gordon Wu, Mieko Toyoda, Bonga Shin, PhD and Ashley Vo. Interleukin 6 (IL-6) a Cytokine Critical to Mediation of Inflammation, AutoImmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade. Transplantation 2017 Jan;101(1):32-44
81. Sethi S, Choi J, Toyoda M, Vo A, Peng A, Jordan SC. Desensitization: Overcoming the Immunologic Barriers to Transplantation. J Immunol Res. 2017 (EPub Jan 3, 2017).
82. Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, Vo A. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade. Transplantation. 2017 Jan. 101(1):32-44.
83. Haas M, Mirocha J, Reinsmoen NL, Vo AA, Choi J, Kahwaji JM, Peng A, Villicana R, Jordan SC. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. Kidney Int. 2017 Mar;91(3):729-737.
84. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R, Secord E, Jordan SC, Stiehm ER, Vo AA, Ballow M. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017 Mar.
85. Kim IK, Choi J, Vo AA, Kang A, Patel M, Toyoda M, Mirocha J, Kamil ES, Cohen JL, Louie S, Galera O, Jordan SC, Puliyanda DP. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients. Transplantation 2017; 101(4): 883-889.
86. Irene K. Kim, MD1, Jua Choi, PharmD1, Ashley A. Vo, PharmD1, Alexis Kang, BS1, Mitasha Patel, BS1, Mieko Toyoda, PhD1, James Mirocha, MS2, Elaine S Kamil, MD1, J. Louis Cohen, MD1, Sabrina Louie, MPH1, Odette Galera, CLS1, Stanley C Jordan, MD1 and Dechu P Puliyanda, MD1. Graft Outcomes and Infectious Complications following Desensitization and Alemtuzumab Induction in Pediatric Kidney Transplant Recipients. Transplantation E pub ahead of press.
87. Jua Choi, Pharm.D1, Olivier Aubert, M.D. 2 Ashley Vo, Pharm.D 1, Alexandre Loupy, M.D., PhD2, Mark Haas, M.D., PhD3, PhD, Dechu Puliyanda, M.D.1, Irene Kim, M.D.1, Sabrina Louie, MPH1, Alexis Kang, BS1, Alice Peng, M.D.1, Joe Kahwaji, M.D.1, Nancy Reinsmoen, PhD3, Mieko Toyoda, PhD4 and Stanley C. Jordan, M.D.1 Assessment of tocilizumab (anti-IL-6R monoclonal) as a treatment for chronic antibody mediated
- Page 16 - Updated –5/26/17 rejection and transplant glomerulopathy in HLA sensitized renal allograft recipients. American J. Transplantation; 2017 Feb 15.
88. Elena E. Perez, MD PhD, Jordan S. Orange, 1 MD PhD, Francisco Bonilla, MD PhD,Javier Chinen MD PhD, Ivan Chinn MD, Morna Dorsey, MD MMSc, Yehia El- Gamal,MD PhD, Terry O. Harville, MD PhD, Elham Hossny, MD PhD, Bruce Mazer, MD,Robert Nelson, MD, Elizabeth Secord MD PhD, Stanley C Jordan, MD, E RichardStiehm, MD, Ashley A. Vo PharmD , and Mark Ballow, MD. Update on Use of Immune Globulin (IG) in Human Disease: A review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. Journal Allergy & Clinical Immunology (Epub ahead of press)
89. Steggerda J, Kang A, Pan S-H, Sundarum V, Nissen N, Klein A, Todo T, Annamalai A, Vo A, Jordan SC and Kim I. Outcomes of highly HLA sensitized patients undergoing simultaneous liver and kidney transplantation: A single center experience with desensitization. Liver Transplantation Proceedings(submitted)
90. Supreet Sethi M.D., Jua Choi, Pharm. D., Mieko Toyoda PhD, Ashley Vo, Pharm.D. Alice Peng, M.D. and Stanley C. Jordan, M.D. Desensitization: Overcoming the Immunologic Barriers to Transplantation. Journal of Immunology Research 2017; (Epub Jan 3, 2017).
91. Mieko Toyoda1, Bong-Ha Shin1, Shili Ge1, James Mirocha3, David Thomas1, Maggie Chu1, Edgar Rodriguez1, Christine Chao1, Anna Petrosyan1, Odette A Galera1, Ashley Vo 2, Jua Choi2, Alice Peng2, and Stanley C Jordan, M.D. Impact of Desensitization on Anti-viral Immunity in HLA-Sensitized Kidney Transplant Recipients. Journal of Immunology Research 2017 (Epub Feb 6, 2017).
92. Irene K. Kim1, Jua Choi1, Ashley Vo 1, Alexis Kang1, Justin Steggerda1, Sabrina Louie1, Mark Haas2, James Mirocha3, J. Louis Cohen1, Helen Pizzo1, Elaine Kamil1, Stanley Jordan1, Dechu Puliyanda1 Risk factors for the development of Antibody-mediated Rejection in Highly Sensitized Pediatric Kidney Transplant Recipients. Pediatric Transplantation (submitted)
93. Toyoda M, Shin BH, Ge S, Mirocha J, Thomas D, Chu M, Rodriguez E, Chao C, Petrosyan A, Galera OA, Vo A , Choi J, Peng A, Kahwaji J, Jordan SC. Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. J Immunol Res. 2017;2017:5672523. doi: 10.1155/2017/5672523. Epub 2017 Feb 6.
INVITED CHAPTERS 1. S. Jordan, A. Peng, and A. Vo. Use of Intravenous Gammaglobulin (IVIG) in Kidney Transplantation. Unimed Use of IVIG in Clinical Practice 2008. - Page 17 - Updated –5/26/17 2. Jordan SC, Toyoda M, Vo AA.. Therapeutic strategies in management of highly-HLA sensitized and ABO-incompatible transplant recipients. Contrib Nephrology 2009; 162:13-26.
3. Ashley A. Vo, George Chaux, and Jeremy Falk. Transplant Immunosuppression. Medical Management of the Thoracic Surgery Patient 2010; Chp 40:352-356.
4. S. Jordan, M. Toyoda, J. Kahwaji, A. Peng, and A. Vo. IVIG: A Modulator of Immunity & Inflammation with Application in Solid Organ Transplantation. Immunotherapy & Transplantation. B. Kaplan Editor. 2012.
5. Jordan SC and Vo A. Use of Intravenous Gammaglobulin in Kidney Transplantation. Unimed. 2nd edition. Immunomodulation with IVIG: Desensitization of Highly-HLA Sensitized Patients. 2013.
6. Jordan SC and Vo A. Evolving Concepts in Desensitization. Clinical Transplants 2013; Chapter 34: 285-292. Terasaki Festschrift Meeting.
7. Joseph Kahwaji, Jua Choi, Stanley Jordan, and Ashley Vo . Recent Advances in Hematology Research: Plasmapheresis and Intravenous Immunoglobulin. Complications of Intravenous Immunoglobulin Therapy. Nova Biomedical 2014. Chapter 2: 21-38.
8. Stanley C. Jordan, Jua Choi, and Ashley Vo. Strategies to Improve Novel Drug Development in Kidney Transplantation Through the Clinical Trials Process. Clinical Transplants 2015. Chapter 16: 163-172.
9. Joseph Kahwaji, Jua Choi, Ashley Vo and Stanley C. Jordan. Immunologic and Infectious Complications in Highly Sensitized Patients Post-Kidney Transplantation. Clinical Transplants 2015. Chapter 26: 265-273.
10. Jordan SC and Vo AA, Intravenous Immunoglobulins in Kidney Transplantation. In: Clinical Use of Immunoglobulins eds. V Wahn and J. Orange UNI-Med Verlag 2009.
11. Jordan SC and Vo AA, Intravenous Immunoglobulins in Kidney Transplantation. In: Clinical Use of Immunoglobulins eds. V Wahn and J. Orange UNI-Med Verlag 2013.
ABSTRACTS AND PRESENTATIONS
1. Asha Moudgil, Ashley A. Vo, Mieko Toyoda, Stanley C. Jordan. Dacluzimab is comparable to Antithymocyte Globulin (ATG) Induction in Preventing Acute Rejection AR Episodes in High Risk Renal Transplant Recipients. Accepted for Poster Presentation at AST (American Society of Transplantation) 1999, Chicago, IL.
2. Stanley C Jordan, Ashley A. Vo, Mieko Toyoda, Asha Moudgil. Preliminary Results from a Randomized, Blinded, Placebo-Controlled Trial of Intravenous Gammaglobulin - Page 18 - Updated –5/26/17 (IVIG) + Pulse Steroids (PS) for the Treatment of Acute Rejection (AR) Episodes in Renal Allograft Recipients. SC Jordan, A. Vo, M. Toyoda, A. Moudgil. Accepted for Poster Presentation at AST 1999, Chicago, IL.
3. Jordan, SC, Vo, A., Toyoda, M., and Moudgil, A. Follow-up Results from a Randomized, Blinded, Placebo-Controlled Pilot Trial of IVIG +pulse steroids (PS) for the Treatment of Acute Rejection (AR) Episodes in Renal Allograft Recipients. WSPR, Carmel, CA, February 9-12, 2000.
4. Ashley A. Vo, Mieko Toyoda, and Stanley C. Jordan. Incidence of CMV Infections in Kidney Transplant Patients Receiving Full Dose Calcineurin Inhibitors vs. Reduced Dose + Zenapax Induction. Abstract submitted to AST 2000 and ASN 2000 (American Society of Nephrology), Toronto, Canada.
5. Gordon Ingle, Asha Moudgil, Ashley A. Vo, Stanley C. Jordan. Daclizumab (DAC) and Mycophenolate Mofetil (MMF) Reduce the Need for Cyclosporine (CSA) in Renal Transplant (RTx) Immunosuppression. Abstract submitted to AST 2000, Chicago, IL and ASN 2000, Toronto, Canada.
6. Stanley C. Jordan, Ashley A. Vo, S. Bunnapradist, Elaine S. Kamil, Mieko Toyoda. Treatment of Active CMV Infection with Oral Ganciclovir in renal allograft recipients: monitoring efficacy with quantitative CMV-PCR. Accepted for Poster Presentation at 2001 AST meeting, Chicago, IL.
7. Stanley C. Jordan, Ashley A. Vo, S. Bunnapradist, Dolly Tyan. Inhibition of Crossmatch (CMX) positivity between donor-recipient pairs using intravenous gammaglobulin (IVIG) with subsequent transplantation. Accepted for Oral Presentation at 2001 AST meeting, Chicago, IL.
8. Ashley A Vo, Stanley C. Jordan, Suphamai Bunnapradist, Mieko Toyoda. CMV Prophylaxis Using Oral Ganciclovir (GCV) and Acyclovir (ACV) in Kidney and Liver Allograft Recipients: Confirmation of Efficacy Using CMV-PCR. Accepted for Poster Presentation at the American Transplant Congress 2002, Washington, DC.
9. Stanley C. Jordan, Ashley A. Vo, Suphamai Bunnapradist, Mieko Toyoda. Successful Use of Oral Ganciclovir (OG) for the Treatment of Intrauterine CMV Infection in a Renal Allograft Recipient. Accepted for Poster Presentation at the American Transplant Congress 2002, Washington, DC.
10. Engle, G., Moudgil, A., Vo, A., and Jordan, SC. Daclizumab and MMF Reduce the Need for CSA Without Increasing the Risk of Acute Rejection in Renal Transplantation. Am. Soc. Transp. Chicago, IL. (May 11-15, 2001).
11. Vo, A., Trac, L., Bunnapradist, S., Tyan, D. Inhibition of Crossmatch Positivity between Donor-Recipient Pairs Using IVIG with Subsequent Transplantation. Am. Soc. Transp. Chicago, IL. (May 11-15, 2001).
- Page 19 - Updated –5/26/17 12. Vo, Ashley, A., Bunnapradist, S., Puliyanda, D., Rodich, G. S., Toyoda, M., and Jordan, S. A Prospective Study of Induction and Maintenance Immunosuppression with Rapamycin, Daclizumab, and Corticosteroids and Low Dose Tacrolimus in Renal Transplantation with Immunologic Monitoring. Accepted for Poster Presentation at the American Society of Nephrology’s Renal Week 2002 (October 30th through November 4th) in Philadelphia, PA.
13. Stanley C. Jordan, Ashley A. Vo, Suphamai Bunnapradist and Dolly Tyan. IVIG Inhibits Crossmatch (CMX) Positivity and Allows Successful Transplantation in Living-Donor and Cadaver Transplant Recipients. Accepted for Oral Presentation at the American Transplant Congress 2002, Washington, DC.
14. Toyoda, M., Puliyanda, D., Jordan, S., Amet, N., Moudgil, A., Vo, A., and Bunnapradist, S. Monitoring Polyoma Virus-BK in Renal Transplant Recipients Using PCR Techniques. Accepted for Poster Presentation at the American Transplant Congress 2002. Accepted for Poster Presentation at the American Society of Nephrology’s Renal Week 2002 (October 30th through November 4th) in Philadelphia, PA.
15. Puliyanda, Dechu, Amet, Nurmamet, Moudgil, Asha, Hilo, Lara, Cam, Vinh, Vo, Ashley, Bunnapradist, S., Jordan, Stanley C., and Toyoda, Mieko. Clinical Significance of Monitoring for Polyoma Virus B-K (BKV) by PCR in Renal Transplant Recipients. Accepted for Poster Presentation at the American Society of Nephrology’s Renal Week 2002 (October 30th through November 4th) in Philadelphia, PA.
16. Bunnapradist, S., Peng, A., Vo, A., Daswani, A., Jordan, S.C. and Takemoto, S.K. Utilization and Results of Simultaneous Heart-Kidney Transplant in the United States: An Analysis of UNOS Renal Registry Database: 1987-2001. Accepted for Oral Presentation to the American Transplant Congress for 2003, Washington, DC.
17. Vo, A., Lukovsky, M., Toyoda, M., Puliyanda, D., Cam, V., Bunnapradist, S., and Jordan, SC. Safety and Adverse Event Profiles of Intravenous Gammaglobulin (IVIG) Products Used for Immunomodulation: A Single Center Experience. Accepted for Oral Presentation to the American Transplant Congress for 2004, Boston, MA.
18. Jordan, SC., Vo, A . A Four Year Follow Up of Rejection Patterns, Treatment and Outcomes in Highly HLA Sensitized Crossmatch (CXM) Positive Patients Transplanted with IVIG Desensitization. Accepted for Oral Presentation to the American Transplant Congress for 2004, Boston, MA.
19. Vo, A., Toyoda, M., Radha, R., Peng, A., Bunnapradist, S., Tyan, D., Lukovsky, M., and Jordan, S. Effect of Induction Therapy Protocols on Transplant Outcomes in Crossmatch Positive Patients Treated with IVIG. Accepted for Oral Presentation to the American Transplant Congress for 2005, Seattle, WA.
- Page 20 - Updated –5/26/17 20. Jordan, S., Vo, A., Radha, R., Ong, G., Naim, M., Peng, A., Bunnapradist, S., and Tyan, D. Outcomes in Highly Sensitized (HS) Patients Transplanted with a Cytotoxicity (CDC) Negative, Donor Specific (DS) Positive T-Cell Flow Cytometry Crossmatch Using Intravenous Gammaglobulin (IVIG) Induction. Accepted for Poster Presentation to the American Transplant Congress for 2005, Seattle, WA.
21. Tyan, D., Vo, A., Radha, R., Ong, G., Naim, M., Peng, A., Bunnapradist, S., and Jordan, S. Outcomes of Highly HLA- Sensitized Patients Treated with Intravenous Gammaglobulin (IVIG) and Transplanted with a Positive Complement-Dependent Cytotoxicity (CDC) Crossmatch (XM). Accepted for Poster Presentation to the American Transplant Congress for 2005, Seattle, WA.
22. Radha, R., Toyoda, M., Puliyanda, D., Vo, A., Tyan, D., and Jordan, S. Monitoring Alloantibody Levels in Highly Sensitized Patients Treated with Rituximab. Accepted for Poster Presentation to the American Transplant Congress for 2005, Seattle, WA.
23. Peng A, Vo A, Bunnapradist S, Jordan SC. Incidence and outcomes of treatment protocols for antibody mediated rejection in highly-HLA sensitized patients transplanted using IVIG desensitization. Accepted for Oral Presentation at the World Transplant Congress, Boston, MA, July 22-26, 2006..
24. Toyoda M, Puliyanda D, Vo A, Pao A, Petrosyan A, Kamil E, Peng A, Bunnapradist S, and Jordan SC. Post-transplant basal ATP levels in T-cells predict risk for viral infections, but not acute rejection in kidney transplant recipients. Accepted for Poster Presentation at the World Transplant Congress, Boston, MA, July 22-26, 2006.
25. Toyoda M, Vo A, Puliyanda D, Pao A, Petrosyan A, Peng A, Bunnapradist S, and Jordan SC. Monitoring T-cell ATP levels in highly-HLA sensitized kidney allograft recipients: Assessment of responses to IVIG therapy and correlation with long term outcomes. Submitted to the World Transplant Congress, Boston, MA, July 22-26, 2006.
26. Vo A, Wechsler E, Jagolino J, Lukovsky M, Sani S, Toyoda M, Peng A, Puliyanda D, and Jordan SC. Monitoring for infectious complications of CAMPATH 1H and Rituxan® induction therapy in cross match positive kidney transplant patients receiving IVIG desensitization. Accepted for Oral Presentation at the World Transplant Congress, Boston, MA, July 22-26, 2006.
27. Vo A, Lukovsky M, Toyoda M, Jagolino J, Sani S, Peng A, and Jordan SC. Impact of post-transplant induction therapy protocols using Zenapax®, Thymoglobulin® or CAMPATH-1H on long term outcomes in cross match positive patients desensitized with IVIG. Accepted for Oral Presentation at the World Transplant Congress, Boston, MA, July 22-26, 2006.
28. Puliyanda D, Toyoda M, Vo A, Bunnapradist S, Peng A, and Jordan SC. Leflunomide treatment of BK viremia in highly-HLA sensitized kidney transplant patients. Accepted for Poster Presentation at the World Transplant Congress, Boston, MA, July 22-26, 2006.
- Page 21 - Updated –5/26/17 29. Vo A, Lukovsky M, Toyoda M, Wechsler E, Peng A, and Jordan SC. Efficacy and safety profiles of subcutaneous CAMPATH 1H administration in cross match positive patients desensitized with IVIG. Accepted for Oral Presentation at the World Transplant Congress, Boston, MA, July 22-26, 2006.
30. Vo A, Lukovsky M, Nakamura A, Peng A, Toyoda M, and Jordan SC. Cost effectiveness of various post-transplant induction protocols in cross match positive allograft recipients desensitized with IVIG. Accepted for Poster Presentation at the World Transplant Congress, Boston, MA, July 22-26, 2006.
31. Nast C, Peng A, Vo, A., Jordan SC. Thymoglobulin® induction therapy: A potential role in the pathogenesis of C4d (+) antibody-mediated rejection (AMR) in highly-HLA sensitized patients desensitized with IVIG. Accepted for Oral Presentation at the World Transplant Congress, Boston, MA, July 22-26, 2006.
32. Toyoda M, Vo, A., Puliyanda D, Pao A, Petrosyan A, Peng A, Bunnapradist M, and Jordan SC. Monitoring immunosuppressive protocols in highly HLA sensitized patients using the T-cell Cylex® assay. American Society of Histocompatibility and Immunogenetics 2006.
33. Toyoda M, Vo, A., Puliyanda D, Pao A, Petrosyan A, Peng A, Bunnapradist M and Jordan SC. Monitoring T-cell ATP levels in highly-HLA sensitized renal allograft recipients: Assessment of responses to IVIG therapy and correlation with long-term outcomes. American Society of Histocompatibility and Immunogenetics, 2006.
34. Reinsmoen N, Vo, A., Toyoda M, Naim R, Ong G, and Jordan SC. HLA specific antibody analysis in highly sensitized patients undergoing desensitization therapy. Submitted to the American Transplant Congress, San Francisco, CA, May 5-9, 2007.
35. Vo, A., Wang J, Weschler E, Yang T, Reinsmoen N, Toyoda M, Peng A, Villicana R, Dafoe D, and Jordan SC. Impact of post-transplant induction therapy protocols using Campath 1H or Zenapax with Rituxan in cross match positive patients desensitized with IVIG. Accepted for Poster Presentation at the American Transplant Congress, San Francisco, CA, May 5-9, 2007.
36. Vo, A., Wang J, Weschler E, Yang T, Toyoda M, Reinsmoen N, Peng A, Villicana R, Dafoe D, and Jordan SC. Analysis of long-term efficacy and safety profiles of subcutaneous Campath 1H administration in CMX positive patients desensitized with IVIG. Accepted for Oral Presentation at the American Transplant Congress, San Francisco, CA, May 5-9, 2007.
37. Vo, A., Wang J, Toyoda M, Reinsmoen N, Lukovsky M, Peng A, Villicana R, Dafoe D, and Jordan SC. Use of single dose IVIG induction therapy at the time of transplantation in patients with historic positive or FCMX positive donor-specific CMXs. Submitted to the American Transplant Congress, San Francisco, CA, May 5-9, 2007.
- Page 22 - Updated –5/26/17 38. Vo, A., Wang J, Toyoda M, Reinsmoen N, Lukovsky M, Peng A, Villicana R, Dafoe D, and Jordan SC. Comparison of two desensitization strategies for highly-HLA sensitized patients using IVIG in standard dose frequency vs. reduced dose frequency + Rituxan®: Efficacy and cost considerations. Accepted for Oral Presentation at the American Transplant Congress, San Francisco, CA, May 5-9, 2007.
39. Vo, A., Toyoda M, Wang J, Lukovsky M, Peng A, Villicana R, Dafoe D, and Jordan SC. A Phase I/II trial to investigate the safety and efficacy of Rituxan® and IVIG as agents to desensitized highly-HLA sensitized dialysis patients awaiting kidney transplantation. Accepted for Oral Presentation at the American Transplant Congress, San Francisco, CA, May 5-9, 2007.
40. Peng A, Vo, A., Dafoe D, Villicana R, Reinsmoen N, Toyoda M, and Jordan SC. Fixed number plasmapheresis followed by high-dose IVIG and Rituxan® for desensitization of highly-HLA sensitized patients and treatment of antibody-mediated rejection. Accepted for Poster Presentation at the American Transplant Congress, San Francisco, CA, May 5- 9 2007.
41. Peng A, Vo, A., Dafoe D, Villicana R, Reinsmoen N, Toyoda M, and Jordan SC. Incidence of antibody mediated rejection and outcomes of various treatment protocols in highly sensitized patients transplanted using desensitization therapy. Accepted for Poster Presentation at the American Transplant Congress, San Francisco, CA, May 5-9, 2007.
42. Toyoda M, Pao A, Vo, A., Lukovsky M, Rada R, Sado T, Baden L, Petrosyan A, and Jordan SC. Pre-transplant donor-specific B-cells in highly-HLA sensitized patients detected by intracellular cytokine flow cytometry predicts antibody-mediated rejection. Accepted for Oral Presentation at the American Transplant Congress, San Francisco, CA, May 5-9, 2007.
43. Ge S, Vo, A., Pao A, Lukovsky M, Petrosyan A, Reinsmoen N, Jordan SC, and Toyoda M. Desensitization of highly-HLA sensitized patients using IVIG and Rituxan® depletes B-cells but leaves T-cell function intact. Accepted for Oral Presentation at the American Transplant Congress, San Francisco, CA, May 5-9, 2007.
44. Lai C, Vo A, Naim R, Ong G, Wang Q, Toyoda M, and Jordan SC. Antibody Analysis of Pre-Transplant Desensitization Protocols for Deceased and Living Related Donor Transplantation. Abstract submitted to ASHI 2007.
45. Ashley A Vo, Robert Chang, Mieko Toyoda, Nancy Reinsmoen, Marina Lukovsky, Alice Peng, Rafael Villicana, Stanley C Jordan. Use of IVIG+ Single Dose Rituximab for Desensitization of Highly-HLA Sensitized Patients Awaiting Kidney Transplantation. Accepted for Oral Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
46. Ashley A. Vo, Robert Chang, Mieko Toyoda, Nancy Reinsmoen, Marina Lukovsky,
- Page 23 - Updated –5/26/17 Alice Peng, Rafael Villicana, Stanley C. Jordan. Desensitization of Highly HLA Sensitized Cross match (+) Patients Awaiting Living Donor (LD) Kidney Transplantation Using IVIG + Rituximab. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
47. Ashley A. Vo, Robert Chang, Mieko Toyoda, Nancy Reinsmoen, Marina Lukovsky, Alice Peng, Rafael Villicana, Stanley C. Jordan. Comparison of Two Desensitization Strategies Using IVIG and Rituximab to Improve Transplantation Rates in Highly-HLA Sensitized Patients (HS) Awaiting Living (LD) and Deceased Donor (DD) Transplants. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
48. Ashley A. Vo, Robert Chang, Mieko Toyoda, Nancy Reinsmoen, Marina Lukovsky, Alice Peng, Rafael Villicana, Stanley C. Jordan. A Novel Therapeutic Approach to Improve Rates and Outcomes of Deceased Donor (DD) Transplants in Highly-HLA Sensitized Patients (HS) Using IVIG + Rituximab. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
49. Shili Ge, Ning-Ning Chai, Ashley Vo , Anna Petrosyan, Andy Pao, Marina Lukovsky, Stanley C. Jordan and Mieko Toyoda. Desensitization (DES) Using Intravenous Immunoglobulin (IVIG) and Rituximab (Ritux) Induces Long-Term Reduction of Anti- HLA Class I Antibody (AB) Levels Without Affecting Total IGG and Anti-CMV IGG Levels in Highly Sensitized (HS) Kidney Transplant Patients (Tx Pts). Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
50. Shili Ge, Andy Pao, Nancy Reinsmoen, Ashley Vo, Robert W. Chang, Alice Peng, Rafael Villicana, Stanley C. Jordan, Mieko Toyoda. Low Allo-Specific CD3-Cell Reactivity Pre-Desensitization (PRE-DES) as Detected By Intracellular Cytokine Flow Cytometry (CFC) Predicts Low Risk for Antibody (AB) Mediated Rejection (AMR) in Highly Sensitized Patients (HS). Accepted for Oral Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
51. Mieko Toyoda, Andy Pao, Ashley Vo, Marina Lukovsky, Raju Radha, Tetsu Sado, Shili Ge, Ning-Ning Chai, Anna Petrosyan, Edwina Skinner, Stanley C. Jordan. Pre- Transplant (Tx) Allo and Donor-Specific (ALLO/DO) Reactivity Detected by Intracellular Cytokine Flow Cytometry (CFC) Assesses the Degree of Sensitization and Predicts Antibody Mediated Rejection (AMR) in Highly Sensitized Patients (HS). Accepted for Oral Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
52. Mieko Toyoda, Andy Pao, Shili Ge, Ashley Vo, Chih-Hung Lai, Marina Lukovsky, Qi Wang, Raju Radha, Geraldine Ong, Tetsu Sado, Kai Cao, Lara Baden, Anna Petrosyan, Edwina Skinner, Nancy Reinsmoen, Stanley C. Jordan. Elevated Allo-Reactivity in Normal Multiparous Females as Detected By Intracellular Cytokine Flow Cytometry (CFC) is Directed Against Paternal HLA Antigens (AGs) and May Impact Risk for
- Page 24 - Updated –5/26/17 Antibody Mediated Rejection (AMR) if Transplanted. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
53. David Thomas, Andy Pao, Ashley Vo, Dechu Puliyanda, Robert W. Chang, Anna Petrosyan, Alice Peng, Rafael Villicana, Elaine Kamil Stanley Jordan, Mieko Toyoda. ATP Levels (ATP) Analyzed by Cylex ImmuKnow Assay (ICF) are Useful to Guide Management of CMV and BKV Infection, but has Limited Utility for EBV. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
54. Reinsmoen L. Nancy, Chih-Hung Lai, Geraldine Ong, Mehrnoush Naim, Ashley Vo, Stanley Jordan. Donor HLA Specific Antibody and Soluble CD30 Levels As Acute Rejection Risk Factors for Patients In High Dose IVIG/Rituximab Desensitization Protocols. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
55. Chih-Hung Lai, Ashley Vo, Mieko Toyoda, Stanley Jordan, Nancy L. Reinsmoen. High Dose IVIG (+/- Rituximab) Desensitization Alters sCD30 and BAFF Levels in Highly HLA Sensitized Patients. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
56. Richard Lee, Alice Peng, Rafael Villicana, Ashley Vo, Donald Dafoe, Robert Chang, Mieko Toyoda, Nancy Reinsmoen, Stanley Jordan. Rates of Acute Rejection (AR) and Treatment Outcomes in Highly-HLA Sensitized Patients (HS) Transplanted After Desensitization with IVIG + Rituximab. Accepted for Oral Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
57. Alice Peng, Ashley Vo, Rafael Villicana, Donald Dafoe, Nancy Reinsmoen, Stanley Jordan. Long Term Graft and Patients Outcomes in Highly-HLA Sensitized (HS) Deceased Donor (DD) Kidney Transplant (KT) Recipients Desensitized with High Dose (H/D) IVIG. Accepted for Oral Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
58. Alice Peng, Ashley Vo, Rafael Villicana, Richard Lee, Donald Dafoe, Nancy Reinsmoen, Edwina Skinner, Stanley Jordan. Long Term Graft and Patient Outcomes in Highly-HLA Sensitized (HS) Patients Desensitized with High Dose (HD) IVIG. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
59. Robert W. Chang, Ashley Vo, Samuel H. Pepkowitz, Ellen Klapper, Alice Peng, Rafael Villicana, Nancy Reinsmoen, Mieko Toyoda, and Stanley C. Jordan. Intravenous Immune Globulin Products Contain Antibodies to Blood Group Antigens and Can Induce Acute Hemolysis in Highly-HLA Sensitized Patients Receiving IVIG for Desensitization. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
- Page 25 - Updated –5/26/17 60. Robert W. Chang, Alice Peng, Rafael Villicana, Ashley Vo, Anna Petrosyan, Nancy Reinsmoen, Stanley C. Jordan, and Mieko Toyoda. Pre-transplant Anti-endothelial Cell Antibody Levels Are Not Predictive of Acute Antibody Mediated Rejection in Renal Allograft Recipients. Accepted for Oral Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
61. Rafael Villicana, Ashley Vo, Alice Peng, Robert Chang, Donald Dafoe, Mieko Toyoda, Nancy Reinsmoen, and Stanley Jordan. Comparison of Outcomes in Older Highly Sensitized Patients Undergoing Desensitization With IVIG + Rituximab to Age Matched Non Sensitized Kidney Transplant Recipients. Accepted for Poster Presentation at the American Transplant Congress, Toronto, Canada, May 31-June 4, 2008.
62. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, Wang Q, Jordan SC. Successful Deceased and Living Donor Kidney Transplantation after Desensitization Therapy in the Presence of Donor Specific Antibodies (DSA): Determination of Acceptable Pre- and Post- transplant DSA Levels. Oral Presentation, WTC 2008, Australia.
63. Ashley A. Vo, Kai Cao, Chih-hung Lai, Nancy Reinsmoen, Mieko Toyoda, Shili Ge, Alice Peng, Rafael Villicana, and Stanley C. Jordan. Long Term Outcomes in Highly-HLA Sensitized (HS) Patients Receiving Desensitization with IVIG and Single-Dose (SD) Rituximab. Accepted for Poster Presentation at the American Transplant Congress, Boston, MA.
64. Ashley A. Vo, Toyoda Mieko, Shili Ge, Kai Cao, Chih-Hung Lai, Nancy Reinsmoen, Alice Peng, Rafael Villicana, and Stanley C. Jordan. Analysis of Subcutaneous (SQ) Campath 1- H Induction Therapy in Highly-HLA Sensitized (HS) Patients Desensitized with IVIG + Rituximab: Three Year Outcomes. Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
65. Ashley A. Vo, Kai Cao, Chih-Hung Lai, Nancy Reinsmoen, Mieko Toyoda, Shili Ge, Alice Peng, Rafael Villicana, and Stanley C. Jordan. Characteristics of Patients Who Developed Antibody Mediated Rejection (AMR) Post-Transplant After Desensitization with IVIG + Rituximab: Analysis of Risk Factors & Outcomes. Accepted for Oral Presentation at the American Transplant Congress 2009, Boston, MA.
66. Ashley A. Vo, Mieko Toyoda, Shili Ge, Chih-Hung Lai, Kai Cao, Nancy Reinsmoen, Alice Peng, Rafael Villicana, and Stanley C. Jordan. Long Term Outcomes of Deceased Donor (DD) Transplants In Highly-HLA Sensitized Patients (HS) Desensitized With IVIG + Single- Dose (SD) Rituximab. Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
67. Nancy L. Reinsmoen, Kai Cao, Chih-Hung Lai, Bernice Coleman, Lawrence SC Czer, Sinan Simsir, Ashley A. Vo, and Stanley C. Jordan. Improving Organ Allocation for Highly Sensitized (HS) Heart (HT) and Kidney (KID) Recipients: Defining Criteria for Unacceptable Antigen (UA) Assignment Using a Calculated PRA (CPRA) and Flow Crossmatch (FXM) Trajectory. Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
- Page 26 - Updated –5/26/17 68. Chih-Hung Lai, Geradline Ong, Menronoush Naim, Kai Cao, Ashley A. Vo, Stanley C. Jordan, and Nancy L. Reinsmoen. Paradigm for Predicting Risk of Antibody Mediated Rejection After Desensitization. Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
69. Kai Cao, Ashley A. Vo, Chih-Hung Lai, Qi Wang, Geraldine Ong, Mehrnoush Naim, Stanley C. Jordan, and Nancy L. Reinsmoen. HLA Mismatching Has No Significant Impact on Kidney Transplant Outcomes of Highly-HLA Sensitized Patients Desensitized With IVIG +/- Rituximab. Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
70. Chih-Hung Lai, Ashley A. Vo, Kai Cao, Stanley C. Jordan and Nancy L. Reinsmoen. Immunological Selection Criteria Identifying Patients for Successful Desensitization (DES) with IVIG and Rituxan. Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
71. Shili Ge, Andy Pao, Nancy Reinsmoen, Ashley A. Vo, Chih-Hung Lai, Nathan Deer, Alice Peng, Kai Cao, Angela Aguiluz, Rafael Villicana, Qi Wang, Artur Karasyov, Stanley C. Jordan and Mieko Toyoda. Monitoring Highly Sensitized Patients (HS) Post-Transplant (TX) by Intracellular Cytokine Flow Cytometry (CFC) Together With Donor Specific Antibody (DSA) And Pre-Desensitization (PRE-DES) B Cell-Cross Match (B-CMX) Predicts Risk of Antibody Mediated Rejection (AMR). Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
72. Shili Ge, Andy Pao, Artur Karasyov, Ashley A. Vo, Nathan Deer, Alice Peng, Anna Petrosyan, Rafael Villicana, Angela Aguiluz, Stanley C. Jordan and Mieko Toyoda. Multiple Doses (MD) of Rituximab Used for Desensitization (DES) and Antibody Mediated Rejection Treatment (AMR RX) in Highly-HLA Sensitized Patients (HS) Prolongs B Cell Depletion, But Does Not Alter Total Immunoglobulin (IG) and Anti-CMV IGG Levels Compared to Single Dose (SD) Rituximab. Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
73. Mieko Toyoda, Shili Ge, Pavel Pichurin, Andy Pao, Ashley A. Vo, Nathan Deer, Angela Aguiluz, Artur Karasyov and Stanley C. Jordan. NK Cells Likely Produce IFNγ in Response to Allo-Antigens (AGS) And Contribute To Antibody Mediated Rejection (AMR) In Highly Sensitized Patients (HS). Accepted for Oral Presentation to the American Transplant Congress 2009, Boston, MA.
74. Mieko Toyoda, Shili Ge, Andy Pao, Chih-Hung Lai, Ashley A. Vo, Qi Wang, Pavel Pichurin, Geraldine Ong, Nathan Deer, Kai Cao, Angela Aguiluz, Artur Karasyov, Nancy Reinsmoen and Stanley C. Jordon. Cellular Allo-Reactivity Against Paternal HLA (PHLA) Antigens (AGS) In Multiparous Normal Females (NF) As Detected By Intracellular Cytokine Flow Cytometry (CFC) Remains Elevated Over Years Despite Diminution Of Anti-HLA Antibody (sp) (AB) Levels, Suggesting Allo-AG Specific Memory Cell Activity. Accepted for Oral Presentation to the American Transplant Congress 2009, Boston, MA.
- Page 27 - Updated –5/26/17 75. Joseph M. Kahwaji, Ashley A. Vo, Mieko Toyoda, Shili Ge, Chih-Hung Lai, Kai Cao, Nancy Reinsmoen, Alice Peng, Raphael Villicana, and Stanley C. Jordan. Clinical and Immunologic Analysis of Factors Predictive of Failure of Desensitization in Highly Sensitized Patients Treated with IVIG and Rituximab. Submitted to American Transplant Congress 2009.
76. Alice Peng, Rafael Villicana, Ashley A. Vo, Nancy Reinsmoen, and Stanley Jordan. Stratification of Highly-HLA Sensitized Deceased Donor (DD) Kidney Transplant (KT) Outcomes Following Desensitization by Positivity of Flow Crossmatch (FCMX) at Transplant. Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
77. Alice Peng, Rafael Villicana, Ashley A. Vo, and Stanley Jordan. Long-Term (1, 3, 5, 7 & 9 Year) Outcomes in Highly-HLA Sensitized Patients Receiving Desensitization. Accepted for Oral Presentation to the American Transplant Congress 2009, Boston, MA.
78. Alice Peng, Rafael Villicana, Ashley A. Vo, and Stanley Jordan. Long Term (1, 3, 5, 7, and 9 Year) Outcomes of Desensitization of Highly-HLA Sensitized (HS) Patients Awaiting Deceased Donor (DD) Transplantation. Accepted for Poster Presentation at the American Transplant Congress 2009, Boston, MA.
79. Rafael Villicana, Alice Peng, Samuel Pekowitz, Ellen Klapper, Ashley A. Vo, Stanley Jordan. ABO Incompatible Kidney Transplantation Using Rituximab, Pre-Transplant Plasmapheresis Followed by High Does IVIG: A Single Center Experience. Accepted for Poster Presentation to the American Transplant Congress 2009, Boston, MA.
80. Rafael Villicana, Shili Ge, Andy Pao, Ashley A. Vo, Nathan Deer, Alice Peng, Angela Aguiluz, Artur Karasyov, Stanley Jordan, Mieko Toyoda. Transplant Nephrectomy (TXNX), Hemodialysis (HD) and Pregnancy (PG) Contributes to Allo-Sensitization (ALLO-STZ) in Highly Sensitized Patients (HS), but Not Ethnicity and Blood Transfusion (BTF), as Assessed by Intracellular Cytokine Flow Cytometry (CFC). Accepted for Poster Presentation to the American Transplant Congress 2009, Boston, MA.
81. Joseph Kahwaji, Ashley Vo, Kai Cao, Chih Hung Lai, Shilie Ge, Mieko Toyoda, Nancy Reinsmoen, Alice Peng, Rafael Villicana, and Stanley Jordan. Analysis of Clinical and Immunologic Factors Associated with Failure of Desensitization in Highly Sensitized Patients Treated with IVIG and Rituximab. Accepted for Poster Presentation to the ASN 2009, San Diego, CA.
82. Ashley Vo, Kai Cao, Chih-Hung Lai, Nancy Reinsmoen, Mieko Toyoda, Shili Ge, Alice Peng, Rafael Villicana, Joseph Kahwaji, and Stanley C. Jordan. IVIG + Single Dose Rituximab Is an Effective Desensitization Strategy for Highly HLA Sensitized Patients. Accepted for Oral Presentation to Joint IPITA-IXA 2009. Venice, Italy.
83. Ashley Vo, Alice Peng, Mieko Toyoda, Joseph Kahwaji, Roland Lee, Jennifer Lin, Shili Ge, Rafael Villicana, and Stanley Jordan. Comparison of Desensitization Using High-Dose (HD) IVIG vs. HD-IVIG + Rituximab in Highly-Sensitized Patients with PRAs > Eighty Percent
- Page 28 - Updated –5/26/17 (HS). Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
84. Ashley Vo, Mieko Toyoda, Joseph Kahwaji, Roland Lee, Jennifer Lin, Alice Peng, Rafael Villicana, Shili Ge, and Stanley Jordan. Predictive Value of Measuring CD4+T-Cell Function (Immuknow®) For Antibody-Mediated Rejection (AMR) and Infectious Complications in Highly-HLA Sensitized (HS) Patients Desensitized with IVIG + Rituximab Followed by Induction Therapy Using Campath 1H or Zenapax. Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
85. Ashley Vo, Roland Lee, Jennifer Lin, Joseph Kahwaji, Mieko Toyoda, Shili Ge, Alice Peng, Rafael Villicana, and Stanley Jordan. Comparison of Induction Therapy with Campath 1H vs. Zenapax® in Highly-HLA Sensitized Patients (HS) Transplanted After Desensitization with IVIG + Rituximab. Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
86. Mieko Toyoda, Shili Ge, Elina Suviolahti, Pavel Pichurin, Andy Pao, Ashley Vo, Nancy Reinsmoen, Nathan Deer, Angela Aguiluz, Artur Karasyov, and Stanley Jordan. IFNγ Production by NK Cells after Allo-Antigen (AG) Exposure is Mediated by Antibody-Dependent Cell Cytotoxicity (ADCC) and Likely Contributes to Antibody & Cell-Mediated Rejection (AMR, CMR) and Acute Tubular Necrosis (ATN) Post-Transplantation (TX) in Highly Sensitized Patients (HS). Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
87. Mieko Toyoda, Elina Suviolahti, Shili Ge, Anna Petrosyan, Andy Pao, Washington Lim, Odette Galera, David Thomas, Ashley Vo, and Stanley Jordan. ATP Levels (ATP) Analyzed By Cylex Immuknow® (IFC) Are Useful to Guide Management of Viral Infection (VI) Even At An Incipient Phase, But Has Limited Utility For Allograft Rejection (AR) Prediction. Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
88. Mieko Toyoda, David Thomas, Odette Galera, Ashley Vo, Alice Peng, Rafael Villicana, Joseph Kahwaji, Elaine Kamil, Dechu Puliyanda and Stanley Jordan. Post-Transplant (TX) Plasma Polyomavirus (sp)-BK (BKV)-PCR Monitoring Intervals of Greater Than Three Months Are a Risk Factor for Persistence of High Plasma BKV Levels Which Could Increase Risk for BKV Associated Nephropathy (BKAN). Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
89. Shili Ge, Andy Pao, Ashley Vo, Nathan Deer, Artur Karasyov, Marina Lukovsky, Anna Petrosyan, James Mirocha, Angela Aguiluz, Stanley Jordan and Mieko Toyoda. Intravenous Immunoglobulin and Rituximab Desensitization (IVIG-Ritux-DES) Allows Successful Transplantation (TX) Without Affecting Total Immunoglobulin (IG), Anti-CMV IG and CMV- Specific Cytotoxic T-Cell (CMV-TC) Levels in Highly HLA-Sensitized Patients (HS PTS). Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
90. Shili Ge, Andy Pao, Nancy Reinsmoen, Ashley Vo, Chih-Hung Lai, Nathan Deer, Artur Karasyov, Alice Peng, Kai Cao, Angela Aguiluz, Rafael Villicana, Qi Wang, Stanley Jordan and
- Page 29 - Updated –5/26/17 Mieko Toyoda. Monitoring Highly Sensitized Patients (HS) Post Transplant (TX) By Intracellular Cytokine Flow Cytometry (CFC) Together With Donor Specific Antibody (DSA) Predicts Risk of Antibody Mediated Rejection (AMR) and Allograft Dysfunction. Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
91. Chih-Hung Lai, Geraldine Ong, Menronoush Naim, Kai Cao, Ashley Vo, Stanley Jordan and Nancy Reinsmoen. Tracking Impact of IVIG and Rituximab Combination Therapy on HLA Antibody Specificities and Strengths. Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
92. Joseph Kahwaji, Mieko Toyoda, Nancy Reinsmoen, James Mirocha, Rafael Villicana, Alice Peng, Stanley Jordan, and Ashley Vo. Infectious Complications Associated with Rituximab for Desensitization Protocols. Accepted for Oral Presentation at the American Transplant Congress 2010, San Diego, CA.
93. Joseph Kahwaji, Mieko Toyoda, Nancy Reinsmoen, Rafael Villicana, Alice Peng, Stanley Jordan and Ashley Vo. Incidence of Leukopenia and Neutropenia in Renal Transplant Recipients Who Received IVIG AND Rituximab for Desensitization. Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
94. Joseph Kahwaji, Mieko Toyoda, Nancy Reinsmoen, James Mirocha, Rafael Villicana, Alice Peng, Stanley Jordan and Ashley Vo. Viral Infections in Renal Transplant Recipients Receiving Rituximab as Part of a Desensitization Protocol. Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
95. Ryu Yu, Alice Peng, Joseph Kahwaji, Ashley Vo, Stanley Jordan, and Rafael Villicana. Use of Deceased Kidney Donors With Acute Kidney Injury to Expand the Deceased Donor Pool. Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
96. Rafael Villicana, Amanda Kim, Shi-Hui Pan, Alice Peng, Joseph Kahwaji, Chih-Hung Lai, Ashley Vo, Nancy Reinsmoen, Stanley Jordan, and Steven Colquhoun. Outcomes of Highly Sensitized Simultaneous Liver-Kidney Transplant Patients. Accepted for Poster Presentation at the American Transplant Congress 2010, San Diego, CA.
97. C. H. Lai, K. Cao, G. Ong, M. Naim, Q. Wang, M. Haas, J. M. Kahwaji, A. Peng, R. Villicana, A. A. Vo, S. C. Jordan, N. L. Reinsmoen. Antibody Testing Strategies for Selection of Deceased Donors (DD) for Broadly Sensitized Patients Following Pre-Transplant Immunomodulatory Therapy. Accepted for Poster Presentation at the American Transplant Congress 2011, Philadelphia, PA.
98. Mieko Toyoda, Gina Ahn, David Thomas, Ashley Vo, Elina Suviolahti, Shili Ge, Stanley C. Jordan. Desensitization (DES) with Intravenous Immunoglobulin and Rituximab (IVIG+Ritux) Does Not Induce Polyomavirus-JC (JCV) Viremia Pre- and Post-Transplant (Tx), Suggesting a Low Risk for Progressive Multifocal Leukoencephalopathy (PML) in Desensitized Patients. Accepted for Oral Presentation at the American Transplant Congress 2011, Philadelphia, PA.
- Page 30 - Updated –5/26/17 99. Alice Peng, Joseph Kahwaji, Ashley Vo, Rafael Villicana, Stanley C. Jordan. Transplant Outcomes of Desensitization with High Dose IVIG and Rituximab in Kidney Recipients with Hepatitis C. Accepted for Poster Presentation at the American Transplant Congress 2011, Philadelphia, PA.
100. Ashley A. Vo, Joseph Kahwaji, Alice Peng, Rafael Villicana, Stanley C. Jordan. Efficacy and Cost Analysis of Desensitization Using IVIG and Rituximab for Transplanting Broadly HLA-Sensitized (HS) Patients. Accepted for Oral Presentation at the American Transplant Congress 2011, Philadelphia, PA.
101. Ashley A. Vo, Mark Haas, Nandana Mapakshi, Nancy Reinsmoen, Joseph Kahwaji, Alice Peng, Rafael Villicana, Stanley C. Jordan. Correlation of Donor Specific Antibody (DSA) Levels with Pathologic Features of Antibody Mediated Rejection (AMR) and Response to Therapy. Accepted for Poster Presentation at the American Transplant Congress 2011, Philadelphia, PA.
102. Bongha Shin, Shili Ge, Artur Karasyov, Ashley Vo, Stanley C. Jordan, Mieko Toyoda. Calcineurin Inhibitors (CNIs), Especially Tacrolimus, Are More Effective Than Other Immunosuppressive Agents in Decreasing IFNγ Release by NK Cells after Activation Via an Antibody-Dependent Cellular Cytotoxicity (ADCC)-Like Mechanism In Vitro. Accepted for Oral Presentation at the American Transplant Congress 2011, Philadelphia, PA.
103. Rafael Villicana, Joseph Kahwaji, Alice Peng, Stanley Jordan, Ashley Vo. ABO- Incompatible Kidney Transplantation Using Subcutaneous Alemtuzumab for Induction without Post Transplant Plasmapheresis. Accepted for Oral Presentation at the American Transplant Congress 2011, Philadelphia, PA.
104. Joseph Kahwaji, Aditi Sinha, Mieko Toyoda, Shili Ge, Nancy Reinsmoen, Chih-hung Lai, Kai Cao, Rafael Villicana, Alice Peng, Stan Jordan, Ashley Vo. Infectious Outcomes in Kidney Transplant Recipients Treated with IVIG and Rituximab (IVIG+RIT) for Desensitization Versus Non-Rituximab Treated Recipients. Accepted for Poster Presentation at the American Transplant Congress 2011, Philadelphia, PA.
105. Joseph Kahwaji, Jim Mirocha, Mieko Toyoda, Alice Peng, Rafael Villicana, Stanley Jordan, Ashley Vo. Infection Rates and Outcomes in Kidney Transplant Recipients Treated with IVIG and Rituximab for Antibody Mediated Rejection (AMR). Accepted for Poster Presentation at the American Transplant Congress 2011, Philadelphia, PA.
106. Shili Ge, Aditi Sinha, Artur Karasyov, Anna Petrosyan, Maria C. Climaco, Darly Lovato, David Thomas, Ashley Vo, Stanley C. Jordan, Mieko Toyoda. Availability of Cytomegalovirus- Specific Cytotoxic T Cells (CMV-TC) after Alemtuzumab (ALEM) Induction May Contribute to Clearance of CMV in Kidney Transplant (TX) Patients Desensitized with IVIG and Rituximab (IVIG/RITUX). Accepted for Poster Presentation at the American Transplant Congress 2011, Philadelphia, PA.
- Page 31 - Updated –5/26/17 107. Elina Suviolahti, Shili Ge, Odette Galera, Ashley Vo, David Thomas, Stanley C. Jordan, Mieko Toyota. ATP Levels Analyzed by Cylex Immuknow® (ICF) Are Useful for Predicting Viral Infections, but Have Limited Utility for Rejection in Highly HLA-Sensitized (HS) Kidney Transplant (Tx) Patients. Accepted for Poster Presentation at the American Transplant Congress 2011, Philadelphia, PA.
108. Joseph Kahwaji, Jim Mirocha, Mieko Toyoda, Alice Peng, Rafael Villicana, Stan Jordan, Ashley Vo. Use of IVIG and Rituximab (IVIG/RIT) for Treatment of Transplant Glomerulopathy (TG) in Renal Allograft Recipients. Accepted for Oral Presentation at the American Transplant Congress 2011, Philadelphia, PA.
109. Ashley Vo, Jua Choi, Joseph Kahwaji, Kristen Cisneros, Alice Peng, Rafael Villicana, Nancy Reinsmoen, Chih-Hung Lai, Kai Cao, and Stanley Jordan. Analysis of Factors Associated with Risk for Antibody-Mediated Rejection in Broadly Sensitized Patients Desensitized for Deceased Donor Transplantation. Accepted for Oral Presentation at the American Transplant Congress 2012, Boston, MA.
110. Ashley Vo, Jua Choi, Joseph Kahwaji, Kristen Cisneros, Alice Peng, Rafael Villicana, Nancy Reinsmoen, Chih-Hung Lai, Kai Cao, and Stanley Jordan. Analysis of Factors Associated with Unresponsiveness to Desensitization Using IVIG and Rituximab in Broadly HLA Sensitized Patients. Accepted for Poster Presentation at the American Transplant Congress 2012, Boston, MA.
111. Reiad Najjar, Joseph Kahwaji, Alice Peng, Rafael Villicana, Stanley Jordan, and Ashley Vo. Long-term Living Donor Outcomes after Desensitization with IVIG and Rituximab (RIT). Accepted for Poster Presentation at the American Transplant Congress 2012, Boston, MA.
112. Ben Beroukhim, Joseph Kahwaji, Alice Peng, Rafael Villicana, Stanley Jordan, and Ashley Vo. Hepatitis C (HepC) Positive Kidney Transplants after Desensitization with IVIG and Rituximab (RIT): A Retrospective Case-Control. Accepted for Poster Presentation at the American Transplant Congress 2012, Boston, MA.
113. Debora Barbosa, Joseph Kahwaji, Dechu Puliyanda, James Mirocha, Alice Peng, Rafael Villicana, Stanley Jordan, Ashley Vo and Mieko Toyoda. Incidence and Severity of BK Viremia(BKV) After Desensitization with IVIG + Rituximab (RIT). Accepted for Oral Presentation at the American Transplant Congress 2012, Boston, MA.
114. Gwendolen Chang, Ashley Vo, Joseph Kahwaji, Jua Choi, Alice Peng, Rafael Villicana, and Stanley Jordan. Long Term Outcomes in HLA-Sensitized Kidney Transplant Patients Using Subcutaneous (SQ) Alemtuzumab for Induction. Accepted for Poster Presentation at the American Transplant Congress 2012, Boston, MA.
115. Gwendolen Chang, Ashley Vo, Joseph Kahwaji, Mieko Toyoda, Jua Choi, Rafael Villicana, Alice Peng, and Stanley Jordan. Viral Infections and Cd4+ T-Cell Function (Immuknow®) in Highly Sensitized Kidney Transplant Recipients Treated With Alemtuzumab
- Page 32 - Updated –5/26/17 Induction. Accepted for Poster Presentation at the American Transplant Congress 2012, Boston, MA.
116. Watanabe Junji, Shili Ge, Anna Petrosyan, Ashley Vo, Artur Karasyov, Gina Ahn, Stanley C Jordan and Mieko Toyoda. Upregulated IL-6, IL-17, C-Reactive Protein (CRP) and Soluble E-Selectin (sES), and Downregulated TGF1 in Patients (Pts) with End Stage Renal Disease (ESRD) Were Similar Between HLA-Sensitized (HS) vs. Non-HS Pts. Accepted for Oral Presentation at the American Transplant Congress 2012, Boston, MA.
117. Kristen Cisneros, Ashley Vo, Jua Choi, and Stanley Jordan. Intravenous Immunoglobulin (IVIG) Administration Can Result in Transient Hepatitis B Core Antibody Positivity: Implications for Clinical Trials. Accepted for Poster Presentation at the American Transplant Congress 2012, Boston, MA.
118. Stanley Jordan, Rock Hsi, Ihab Abumuhor, Ellen Klapper, Ashley Vo. Assessment of Anti-A and Anti-B Antibody Titers in Different IVIG Preparations: Correlation with Risk for Hemolysis. Accepted for Poster Presentation at the American Transplant Congress 2013, Seattle, WA/. May 19-22, 2013.
119. Ashley Vo, Jua Choi, Marina Lukovsky, Mieko Toyoda, Shili Ge, Joseph Kahwaji, Alice Peng, Rafael Villicana, Reiad Najjar, and Stanley C Jordan. Interim Analysis of a Double- Blinded Placebo Controlled Trial of IVIG v. IVIG + Rituximab for Desensitization of Highly- HLA Sensitized (PRA>80%) (HS) Deceased Donor (DD) Candidates. Accepted for Oral Presentation at the American Transplant Congress 2013, Seattle, WA, May 19-22, 2013.
120. Ashley Vo, Jua Choi, Joseph Kahwaji, Alice Peng, Rafael Villicana, Reiad Najjar, Stanley C Jordan. Long Term Outcomes of Highly-HLA Sensitized (PRA>80%) (HS) Patients Receiving Desensitization with IVIG or IVIG + Rituximab: A Retrospective, Single-Center Analysis. Accepted for Poster Presentation at the American Transplant Congress 2013, Seattle, WA, May 19-22, 2013.
121. Stanley Jordan, Jua Choi, Rafael Villicana, Alice Peng, Joseph Kahwaji, Reiad Najjar, Ashley Vo. Eculizumab (Anti-C5) for Treatment of Severe Antibody-Mediated Rejection (ABMR) and Recurrent C3 Glomerulonephritis in Renal Allografts: A Single Center Experience. Accepted for Oral Presentation at the American Transplant Congress 2013, Seattle, WA, May 19-22, 2013.
122. Gwendolen Chang, Ashley Vo, Stanley Jordan. Long Term (5-Year) Outcomes Using Subcutaneous Alemtuzumab for Induction in Highly-HLA-Sensitized (HS) Kidney Transplant Recipients. Accepted for Poster Presentation at the American Transplant Congress 2013, Seattle, WA, May 19-22, 2013.
123. Reiad Najjar, Joseph Kahwaji, Deepika Kancherla, Alice Peng, Rafael Villicana, Stanley Jordan, Ashley Vo and Mark Haas. Histopathologic Scoring and Outcomes in Transplant Glomerulopathy (TG). Accepted for Poster Presentation at the American Transplant Congress 2013, Seattle, WA, May 19-22, 2013.
- Page 33 - Updated –5/26/17 124. Bongha Shin, Junji Watanabe, Shili Ge, Ashley Vo, Stanley C. Jordan and Mieko Toyoda. Plasma soluble IL-6 receptor (sIL-6R) levels are significantly elevated during antibody-mediated rejection (ABMR) in highly HLA-sensitized renal allograft recipients (HS Pts). Accepted for Poster Presentation at the American Transplant Congress in Seattle, WA, May 19-22, 2013.
125. Ashley A Vo, Jua Choi, Kristen Cisneros, Joseph Kahwaji, Mieko Toyoda, Shili Ge, Alice Peng, Rafael Villicana, and Stanley C. Jordan. A Phase I/II Trial of Tocilizumab (Anti-IL- 6 Receptor) + Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients. Accepted for Oral Presentation at the 2014 World Transplant Congress in San Francisco, CA, July 26-31.
126. Ashley A Vo, Aditi Sinha, Mark Haas, Jua Choi, Jim Mirocha, Joseph Kahwaji, Alice Peng, Rafael Villicana, and Stanley C. Jordan. Factors Predicting Antibody Mediated Rejection (ABMR) & Graft Loss in Highly-HLA (HS) Sensitized Patients Transplanted After Desensitization (DES). Submitted to the 2014 World Transplant Congress in San Francisco, CA, July 26-31.
127. Stanley C. Jordan, Jua Choi, Ashley A Vo, Joseph Kahwaji, Alice Peng, Rafael Villicana, and Mark Hass. Assessment of Eculizumab (Anti-C5) Therapy for Treatment of Severe Antibody Mediated Rejection Episodes (ABMR). Accepted for Poster Presentation at the 2014 World Transplant Congress in San Francisco, CA, July 26-31.
128. Jua Choi, Joseph Kahwaji, Ashley A Vo, Dechu Puliyanda, Alice Peng, Rafael Villicana and Stanley C. Jordan. Tocilizumab (Anti-IL6-Receptor) Therapy for Donor-Specific Antibody (DSA+) Antibody Mediated Rejection (ABMR+) Resistant to IVIG + Rituxan Treatment. Accepted for Oral Presentation at the 2014 World Transplant Congress in San Francisco, CA, July 26-31.
129. Pantarapha Wongsaroj, Joseph Kahwaji, Ashley A Vo, Jua Choi, Rafael Villicana, Alice Peng, and Stanley C. Jordan. Belatacept vs. Tacrolimus: Clinical Outcomes in De Novo Kidney Transplant Recipients. Accepted for Poster Presentation at the 2014 World Transplant Congress in San Francisco, CA, July 26-31.
130. Junji Watanabe, Cynthia C. Nast, Shili Ge, Ashley A Vo, Alice Peng, Rafael Villicana, Joseph Kahwaji, Stanley C. Jordan and Mieko Toyoda. Elevated Blood IFN, IL-6, IL-10 and IL-17A Levels are Associated with Allograft Rejection (AR) in HLA-sensitized (HS) Kidney Transplant Recipients (Tx Pts). Accepted for Poster Presentation at the 2014 World Transplant Congress in San Francisco, CA, July 26-31.
131. Junji Watanabe, Cynthia C. Nast, Shili Ge, Ashley A Vo, Alice Peng, Rafael Villicana, Joe Kahwaji, Stanley C. Jordan and Mieko Toyoda. Elevated Levels of IL-6/IL-17A/IFNγ in Donor Specific Antibody (DSA)-Mediated Allograft Rejection (ABMR) Suggest Induction of Cell-Mediated Inflammation by DSAs. Accepted for Poster Presentation at the 2014 World Transplant Congress in San Francisco, CA, July 26-31.
- Page 34 - Updated –5/26/17 132. Shili Ge, Artur Karasyov, Anna Petrosyan, Jua Choi, Darly Lovato, Joseph Kahwaji, Jerome GL Lluz, Ashley Vo, Elen Hayrapetyan, Stanley C. Jordan and Mieko Toyoda. Belatacept (CTLA4-Ig) Shows Minimal Suppression of CMV-specific Memory T Cell (CMV-T) and Antibody (CMV-Ab) in CMV Sero (+) Kidney Transplant Recipients (Tx Pts). Accepted for Poster Presentation at the 2014 World Transplant Congress in San Francisco, CA, July 26-31.
133. Shili Ge, David Thomas, Joseph Kahwaji, Maggie Chu, Jua Choi, Karine Galfayan, Artur Karasyov, Ashley Vo, Odette Galera, Alice Peng, Rafael Villicana, Stanley C. Jordan and Mieko Toyoda. Risk Factors for Viremia in Kidney Transplant Recipients (Pts) receiving Belatacept (CTLA4-Ig). Accepted for Poster Presentation at the 2014 World Transplant. Congress in San Francisco, CA, July 26-31.
134. Jolanta Kowalewska, Hedyeh Shafi, Cynthia C Nast, Arkadiusz Gertych, Ashley A Vo, Mieko Toyoda, and Stanley C Jordan. Expression of IL-6 and its receptor IL-6Rα is increased in kidney allografts with antibody mediated rejection. Submitted to the 2014 World Transplant Congress in San Francisco, CA, July 26-31.
135. Kahwaji J, Choi J, Vo A, Jordan SC. Immunologic and Infectious Complications in Highly Sensitized Patients Post-Kidney Transplantation. Clin Transpl. 2015;31:265-273.
136. Vo AA, Zeevi A, Choi J, Cisneros K, Toyoda M, Kahwaji J, Peng A, Villicana R, Puliyanda D, Reinsmoen N, Haas M, Jordan SC. A phase I/II placebo-controlled trial of C1 inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation. 2015 Feb;99(2):299-308.
137. Ashley A. Vo, Jua Choi, Joseph Kahwaji, Dechu Puliyanda, Alice Peng, Rafael Villicana, and Stanley C. Jordan. Long-Term Analysis of a Placebo-Controlled Trial of C1-INH for Prevention of Antibody-Mediated Rejection. Accepted for Oral Presentation at the American Transplant Congress 2015, Philadelphia, PA, May 2-6, 2015.
138. Ashley A. Vo, Jua Choi, Irene Kim, Joseph Kahwaji, Alice Peng, Rafael Villicana, and Stanley C. Jordan. Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES with IVIG + Rituximab. Accepted for Oral Presentation at the American Transplant Congress 2015, Philadelphia, PA, May 2-6, 2015.
139. Ashley A. Vo, Shili Ge, Anna Petrosyan, Mieko Toyoda, Jua Choi, Joseph Kahwaji, Alice Peng, Rafael Villicana, and Stanley C. Jordan. Incidence and Clinical Severity of Hypogammaglobulinemia (Hypo-IgG) in Highly-HLA Sensitized Patients (HS) Undergoing Desensitization (DES). Accepted for Poster Presentation at the American Transplant Congress 2015, Philadelphia, PA, May 2-6, 2015.
140. Joseph Kahwaji, Patarapha Wongsaroj, Jua Choi, Alice Peng, Rafael Villicana, Stanley Jordan and Ashley Vo. De Novo Donor Specific Antibody (DSA) after Treatment of BK
- Page 35 - Updated –5/26/17 Infection with Intravenous Immunoglobulin (IVIG). Accepted for Oral Presentation at the American Transplant Congress 2015, Philadelphia, PA, May 2-6, 2015.
141. Joseph Kahwaji, Sabrina Louie, Ashley Vo, Jua Choi, Mieko Toyoda, Shili Ge, Patarapha Wongsaroj, Alice Peng, Rafael Villicana and Stanley Jordan. A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients following Desensitization with IVIG and Rituximab: Interim Analysis. Accepted for Poster Presentation at the American Transplant Congress 2015, Philadelphia, PA, May 2- 6, 2015.
142. Shili Ge, Joe Kahwaji, Maggie Chu, Artur Karasyov, Maria G Castro, Elen Hayrapetyan, Darly Lovato, David Thomas, Jua Choi, Sabrina Louie, Ashley Vo, Stanley C Jordan and Mieko Toyoda. Assessment of Viral-Specific Memory T Cell Responses and Infection Rates in HLA-Sensitized (HS) Kidney Transplant Patients (Tx Pts) Treated with Everolimus & Low-Dose Tacrolimus (Eve/Tac). Accepted for Poster Presentation at the American Transplant Congress 2015, Philadelphia, PA, May 2-6, 2015.
143. Hao Zhang, David Thomas, Jolanta Kowalewska, Elina Suviolahti, Hedyeh Shafi, Cynthia C Nast, Arkadiusz Gertych, Ashley A Vo, Mark Haas, Stanley C Jordan, and Mieko Toyoda. Differentially Expressed IL-6Rα and GP130 Genes in Kidney Biopsies (Bxs) Suggests Different Roles of IL-6 Signaling in Antibody (AMBR)- and Cell (CMR)- Mediated Rejection. Accepted for Poster Presentation at the American Transplant Congress 2015, Philadelphia, PA, May 2-6, 2015.
144. Vo A, Zhang X, Williamson S, Myers K, Reinsmoen N, Choi J, Kahwaji J, Peng A, Villicana R, Jordan S. Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES). Am J Transplant. 2016;16 (suppl 3). Accepted for Oral Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
145. Vo A, Choi J, Kahwaji J, Mirocha J, Peng A, Villicana R, Jordan S. Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES). Am J Transplant. 2016;16 (suppl 3). Accepted for Oral Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
146. Vo A, Boutsicaris C, Zhang X, Reinsmoen N, Choi J, Jordan S. Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES). Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
147. Choi J, Vo A, Haas M, Puliyanda D, Louie S, Peng A, Kahwaji J, Villicana R, Kim I, Mirocha J, Jordan S. Anti-IL6R Therapy (Tocilizumab) Improves Long-Term Patient & Graft Survival in Patients with Chronic Antibody-Mediated Rejection and Transplant
- Page 36 - Updated –5/26/17 Glomerulopathy. Am J Transplant. 2016;16 (suppl 3). Accepted for Oral Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
148. Choi J, Jordan S, Vo A. First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection. Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
149. Kim I, Choi J, Vo A, Kang A, Toyoda M, Mirocha J, Kamil E, Louie S, Galera O, Jordan S, Puliyanda D. Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation. Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
150. Kim I, Choi J, Vo A, Louie S, Mirocha J, Jordan S, Kamil E, Puliyanda D. Factors Predicting Risk for Antibody-Mediated Rejection in Highly Sensitized Pediatric Renal Transplants. Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
151. Nejad A, Vo A, Choi J, Jordan S. Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES). Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
152. Choi J, Kahwaji J, Vo A, Louie S, Kang A, Peng A, Villicana R, Puliyanda D, Kim I, Jordan S. Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab- Based Desensitization (DES). Am J Transplant. 2016;16 (suppl 3). Accepted for Oral Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
153. Zhang X, Naim M, Vo A, Jordan S, Reinsmoen N. Impact of New Kidney Allocation System on Transplant Rates for Highly Sensitized Patients-Center Specific Study. Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
154. Jordan S, Choi J, Shin B, Kahwaji J, Ge S, Thomas D, Vo A, Galera O, Villicana R, Peng A, Toyoda M. Incidence of Viral Infections in HLA-Sensitized Patients (HS Pts) Desensitized with IVIG + Rituximab (DES) Compared to Non-HS Pts Receiving Standard Immunosuppression. Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
155. Choi J, Shin B, Kahwaji J, Ge S, Thomas D, Vo A, Galera O, Villicana R, Peng A, Jordan S, Toyoda M. EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig). Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
- Page 37 - Updated –5/26/17 156. Shin B, Choi J, Kahwaji J, Ge S, Thomas D, Vo A, Galera O, Villicana R, Peng A, Jordan S, Toyoda M. Examining the Risk for Post-Transplant Viral Infections and Lymphoproliferative Disorder (PTLD) in Kidney Transplant Patients (Pts) Receiving Calcineurin Inhibitor-Based Immunosuppression (CNI-IS) Compared to Belatacept (CTLA4Ig). Am J Transplant. 2016;16 (suppl 3). Accepted for Oral Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
157. Shin B, Choi J, Kahwaji J, Ge S, Thomas D, Vo A, Galera O, Villicana R, Peng A, Jordan S, Toyoda M. Examining the Risk for Post-Transplant Viral Infections and Lymphoproliferative Disorder (PTLD) in Kidney Transplant Patients (Pts) Receiving Calcineurin Inhibitor-Based Immunosuppression (CNI-IS) Compared to Belatacept (CTLA4Ig). Am J Transplant. 2016;16 (suppl 3). Accepted for Oral Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
158. Jordan S, Choi J, Zhang X, Haas M, Peng A, Kahwaji J, Villicana R, Vo A. Initial Experience with the Bacterial Enzyme IdeS® (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Patients. Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
159. Shin B.-H, Ge S, Choi J, Kahwaji J, Vo A, Petrosyan A, Jordan S, Toyoda M. The Effect of Tocilizumab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ. Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
160. Zhang H, Kahwaji J, Li P, Ge S, Thomas D, Nast C, Vo A, Haas M, Jordan S, Toyoda M. Assessment of mRNA Gene Profiles in Plasma Exosome to Predict Risk for Antibody- Mediated Rejection (ABMR) of Renal Allografts. Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
161. Shin B.-H, Ge S, Choi J, Kahwaji J, Vo A, Petrosyan A, Jordan S, Toyoda M. The Effect of Tocilizumab Treatment (TCZ-Rx) on Total IgG and Anti-CMV-IgG Levels in HLA- Sensitized (HS) Kidney Transplant Patients. Am J Transplant. 2016;16 (suppl 3). Accepted for Poster Presentation at the American Transplant Congress 2016, Boston, June 11-15, 2016.
162. A A. Vo, PharmD1, J Choi, PharmD1, I Kim, MD1, E Huang, MD1, S Louie, MPH1, A Kang, BA1, S Williamson, RN1, K Myers, RN1, A Peng, MD1, R Najjar, MD1 and S C Jordan, MD1 . Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant. Accepted for Poster Presentation at the American Transplant Congress 2017.
163. A A Vo, PharmD1, J Choi, PharmD1, A Peng, MD1, K Lim, PharmD1, L Varanasi, MD1, R Najjar, MD1, E Huang, MD1, D Puliyanda, MD1 and S C Jordan, MD. Update of a
- Page 38 - Updated –5/26/17 Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA sensitized patients. Accepted for Poster Presentation at the American Transplant Congress 2017.
164. A A Vo, PharmD1, S Williamson, RN1, K Myers, RN1, E Huang, MD1, J Choi, PharmD1, X Zhang, PhD2, A Peng, MD1, R Najjar, MD1 and S C Jordan, MD1. Assessing The Impact of The New Kas on Transplant Rates in Highly-HLA Sensitized (HS) Patients after Desensitization (DES) 2yrs Post Implementation. Accepted for Poster Presentation at the American Transplant Congress 2017.
165. Edmund Huang1, Stanley Jordan1, Reiad Najjar1, Alice Peng1 and Ashley Vo1. Waitlist Desensitization and the Rate of Deceased Donor Kidney Transplantation After Implementation of the Kidney Allocation System. Accepted for Poster Presentation at the American Transplant Congress 2017.
166. Reiad Y Najjar, MD, Edmund Huang, MD, Ashely A Vo, Pharm,D, Jua Cho, Pharm D, Sabrina Louis, Aleix Hang, Alice Peng, MD and Stanley Jordan, MD. IVIG + Rituximab as Desensitization Agents to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly HLA Sensitized (HS) Awaiting Deceased Donor Transplantation. Accepted for Poster Presentation at the American Transplant Congress 2017.
167. Supreet Sethi, M.D. 1, Ashley Vo, PharmD1, Edmund Huang, M.D. 1, Laalasa Varanasi, M.D. 1, Jua Choi, PharmD1, Alice Peng, M.D. 1, Reiad Najjar, M.D. 1 and Stanley Jordan, M.D. 1Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience. Accepted for Poster Presentation at the American Transplant Congress 2017.
168. Supreet Sethi1, Ashley Vo1, Edmund Huang1, Laalasa Varanasi1, Jua Choi1, Alice Peng1, Reiad Najjar1 and Stanley Jordan1. Chronic Antibody Mediated Rejection (cABMR) in ABOIncompatible and ABOCompatible Kidney Transplants: A Single US Center Experience. Accepted for Poster Presentation at the American Transplant Congress 2017.
169. Hao Zhang1, Cynthia C Nast2, Janice Doldron2, Mandy Cheung2, James Mirocha3, Joseph Kahwaji1, Ashley A Vo1, Stanley C Jordan1 and Mieko Toyoda1. Biopsies (Bx) of Renal Allografts with Antibody- + Cell-Mediated Rejection (ABMR/CMR) Exhibit Gene Expression Signatures from Both Types of Rejection. Accepted for Poster Presentation at the American Transplant Congress 2017.
170. Hao Zhang1, Cynthia C Nast2, Janice Doldron2, Mandy Cheung2, James Mirocha3, Joseph Kahwaji1, Ashley A Vo1, Stanley C Jordan1 and Mieko Toyoda1.Similar Elevation of Gene Expression Associated with Antibody-Mediated Rejection (ABMR) of Renal Allografts Can be Detected in both Plasma Exosomes (pExo) and Biopsies (Bx) by Assessing mRNATranscript Profiles. Accepted for Poster Presentation at the American Transplant Congress 2017.
171. Shili Ge, Ph.D., MD. 1, BongHa Shin, Ph.D. 1, James Mirocha, MS. 1, David Thomas, BS.1, Maggie Chu, BS. 1, Edgar Rodriguez, BS. 1, Christine Chao, BS. 1, Anna Petrosyan,
- Page 39 - Updated –5/26/17 MS. 1, Odette A Galera, BS. 1, Ashley Vo, PharmD.1, Jua Choi, PharmD.1, Alice Peng, MD. 1, Joseph Kahwaji, MD. 1, Stanley C Jordan, MD. 1 and Mieko Toyoda, Ph.D. 1. IVIg+Rituximab Desensitization (DES) Combined with Alemtuzumab (ATZ) Induction Does Not Increase Risk for Viral Infections (VIs) and Associated Complications in HLAsensitized (HS) Kidney Transplant Patients (KTx Pts). Accepted for Poster Presentation at the American Transplant Congress 2017.
172. Shili Ge, Maggie Chu, Jua Choi, Sabrina Louie, Alexis G Kang, Ashley Vo, Alice Peng, Stan C. Jordan, Mieko Toyoda. IdeS, An IgG Endopeptidase, Effectively Cleaves Anti- HLA Antibody (Ab), Resulting in Inhibition of Anti-HLA Ab-Mediated NK Cell Activation and Ab-Dependent Cell-Mediated Cytotoxicity (ADCC) in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts).
173. S Jordan, MD1, J Choi, PharmD1, C Kjellman, PhD2, L Winstedt, PhD2, X Zhang, PhD4, S Louie, MPh1, A Kang, BS1, M Haas, MD, PhD3 and A Vo, PharmD1. Experience with The Bacterial Enzyme IdeS (IgG Endopeptidase) for Desensitization of HighlyHLA Sensitized (HS) Kidney Allograft Recipients. Accepted for Poster Presentation at the American Transplant Congress 2017.
174. Stanley C Jordan, MD1, Jua Choi, PharmD1, Mansour Azim, MD1, Ashley Vo, PharmD1 and Hai Tran, PharmD2. Importance of IL6 & VEGF in Mediation of Capillary Leak Syndrome (CLS): Response to Treatment with Tocilizumab (antiIL6R,TCZ) & Bevacizumab (antiVEGF). Accepted for Poster Presentation at the American Transplant Congress 2017.
175. Jua Choi, PharmD1, Alice Peng, MD1, Ashley Vo, PharmD1, Edmund Huang, MD1, Reiad Najjar, MD, PhD1, Sabrina Louie, MPh1, Allie Kang, BS1, Shili Ge, PhD1, Mieko Toyoda, PhD1, Xiaohai Zhang, PhD1 and Stanley Jordan, MD1. Experience with Belatacept (CTLA4Ig) Conversion in Highly HLA Sensitized (HS) and ABOincompatible (ABOi) Patients who Received Incompatible Kidney Transplants Post Desensitization (DES). Accepted for Poster Presentation at the American Transplant Congress 2017.
176. J Choi, PharmD1, O Aubert, MD2, A Vo, PharmD1, A Loupy, MD, PhD2, M Haas, MD, PhD3, S Louie, Mph1, A Kang, BS1, A Peng, MD1, R Najjar, MD1, E Huang, M.D. 1,M Toyota, PhD5, X Zhang, PhD4 and S C Jordan, MD1. Safety & Long Term Outcomes of Tocilizumab (Antiil6R, TCZ) Therapy in Treatment of Chronic Antibody Mediated Rejection (CABMR) & Transplant Glomerulopathy (TG) in Highly HLA Sensitized (HS) Patients (Pts). Accepted for Poster Presentation at the American Transplant Congress 2017.
177. Jua Choi, Pharm.D1, Ashley Vo, Pharm.D1, Edmund Huang, M.D. 1, Sabrina Louie, MPH1, Alexis Kang, B.S. 1, Alice Peng, M.D. 1, Reiad Najjar, M.D. 1 and Stanley C Jordan, M.D. 1. Experience with Obinutuzumab (Type II AntiCD20) in Kidney Transplant Patients with Donor Specific Antibody (DSA+) Antibody Mediated Rejection. Accepted for Poster Presentation at the American Transplant Congress 2017.
- Page 40 - Updated –5/26/17 178. Alice Peng, MD1, Donald Dafoe, MD1, Jua Choi, PharmD1, Ashley Vo, PharmD1, Xiaohai Zhang, PhD1, Reiad Najjar, MD1, Edward Huang, MD1 and Stanley C Jordan, MD1. Anti-Angiotensin Type 1 Receptor Antibodies Associate With Rejection in Simultaneous Pancreas And Kidney Transplant And Pancreas Transplant Alone Recipients. Accepted for Poster Presentation at the American Transplant Congress 2017.
LECTURE & PRESENTATION 1. Vo, A. Invited Lecture -- Immunosuppression in Solid Organ Transplant. February 2005. Cedars-Sinai Medical Center, Los Angeles, CA.
2. Vo, A. Invited Lecture -- Challenges and complications of IVIG use in clinical practice. Renal Grand Rounds. March 2005. Cedars-Sinai Medical Center, Los Angeles, CA.
3. Vo, A. Invited Lecture -- IGIV Therapy: Clinical and Pharmaceutical Considerations for 2006. Held during the 2005 ASHP Midyear Clinical Meeting. December 2005. Las Vegas Hilton, Las Vegas, NV.
4. Vo, A. Invited Lecture -- Immunosuppression in Solid Organ Transplant. February 2006. Veteran Administration of West LA, Los Angeles, CA.
5. Vo, A. Invited Lecture -- Update on Immunosuppression in Solid Organ Transplant. March 2006. ACC Clinic, Cedars-Sinai Medical Center, Los Angeles, CA.
6. Vo, A. Invited Lecture -- Kidney Transplantation at Cedars-Sinai Medical Center. March 2006. Case Management Conference, Cedars-Sinai Medical Center, Los Angeles, CA.
7. Vo, A. Invited Lecture -- Care of the Critically Ill Cardiothoracic Surgical Patient: Transplant Immunosuppression. March 2006. Cedars-Sinai Medical Center, Los Angeles, CA.
8. Vo, A. Invited Lecture -- “Transplants and You”: Immunosuppression in Solid Organ Transplant. June 2006. American Association of Kidney Patients – Los Angeles Chapter. Skirball Cultural Center, Los Angeles, CA.
9. Vo, A. Invited Lecture -- Update on Transplant Immunosuppression and on Transplant Immunotherapy Program Protocols. September 2006. Kidney Transplant Journal Club, Cedars- Sinai Medical Center, Los Angeles, CA.
10. Vo, A. Invited Lecture -- Review of Transplant Immunosuppression. August 2007. ACC Clinic, Cedars-Sinai Medical Center, Los Angeles, CA.
- Page 41 - Updated –5/26/17 11. Vo, A. Invited Lecture -- Challenges and Complications of IVIG Use in Clinical Practice. August 2007. Department of Pharmacy, Cedars-Sinai Medical Center, Los Angeles, CA.
12. Vo, A. Invited Lecture -- Antibody Mediated Rejection. September 2007. Advances in Transplantation Pre-Conference; La Jolla, CA.
13. Vo, A. Invited Lecture -- Management of Highly Sensitized Renal Transplant Recipient. November 2007. Visiting Professor at Toronto University Hospital, Toronto, Canada.
14. Vo, A. Invited Lecture -- Role of Pharmacist in Management of Highly Sensitized Patients. November 2007. Second Annual Transplant Pharmacist Education Day. Toronto, Canada.
15. Vo, A. Invited Lecture -- Management of Highly Sensitized Renal Transplant Recipient. February 2008. Division of Nephrology, Harbor UCLA, Los Angeles, CA.
16. Vo, A. Invited Lecture -- Management of Highly Sensitized Renal Transplant Recipient. February 2008. Division of Kidney Transplant, University of Southern California, Los Angeles, CA.
17. Vo, A. Invited Lecture -- Challenges and Complications of IVIG Use in Clinical Practice. March 11, 2008. Present to Nephrologists at Cedars-Sinai Medical Center, Los Angeles, CA.
18. Vo, A. Invited Lecture -- Economic Impact and Side Effect Profile of Desensitization Protocol. October 2008. Advances in Desensitization for Transplantation: 2008, Viceroy, Santa Monica, CA.
19. Vo, A. Invited Lecture -- Economic Impact and Side Effect Profile of Desensitization Protocol. November 2008. ASN 2008, Philadelphia, PA.
20. Vo, A. Invited Lecture -- Pharmacological Management of Transplant Patients. December 2008. Overview & Management of Complex Med-Surgical and Transplant Patients. Cedars-Sinai Medical Center, Los Angeles, CA.
21. Vo, A. Invited Lecture -- Pharmacy Considerations in the Selection and Implementing of Desensitization Protocols. January 2009. Management of The Highly Sensitized Patient: Clinical, Logistical & Financial Considerations. Pre-ASTS Symposium, Marcos Island, FL.
22. Vo, A. Invited Lecture -- Pharmaceuticals in Organ Transplantation. March 2009. Invited Lecture: OptumHealth Care Solutions 10th Annual Innovations in Transplantation and Treatment of Complex Medical Conditions Conference. San Diego, CA.
23. Vo, A. Invited Lecture -- The Transplantation Society: New Key Opinion Leader 13th Annual Meeting. July 16-19, 2009. Invited Lecture: Pushing The Envelope of Incompatible
- Page 42 - Updated –5/26/17 Transplantation: Desensitization With IVIG + Single Dose Rituximab – A Single Center Experience. Jackson Hole, WY.
24. Vo, A. Invited Lecture -- NATCO 34TH Annual Meeting. August 2-5, 2009. Antibody Lowering Treatment Outcomes for the Kidney Transplant Recipient. Las Vegas, NV.
25. Vo, A. Invited Lecture -- Continuing Education for CSMC Department of Pharmacy: Immunosuppression for Organ Transplant. September 2009. Cedars-Sinai Medical Center, Los Angeles, CA.
26. Vo, A. Invited Lecture – CSMC Patient Support Group: Transplant Immunosuppression: What Patients Need to Know. February 2010. Cedars-Sinai Medical Center, Los Angeles, CA.
27. Vo, A. Invited Lecture -- The Transplant Series for Department of Pharmacy: Update on Transplant Immunosuppression & Post-op Management of Kidney Transplant Recipients. February 2010. Cedars-Sinai Medical Center, Los Angeles, CA.
28. Vo, A. Invited Lecture -- CSMC & West LA VA Nephrology Fellows: Transplant Immunosuppression in Kidney Transplant Recipients. March 2010. VA, Los Angeles, CA.
29. Vo, A. Invited Lecture -- ATC Meeting: Long-Term Results of Deceased Donor Desensitization. May 3, 2010. San Diego, CA.
30. Vo, A. Invited Lecture – Nursing Continuing Education: Overview of Immunosuppression. May 12, 2010. Cedars-Sinai Medical Center, Los Angeles, CA.
31. Vo. A. Invited Lecture -- ASTS Transplant Fellowship Lecture: Immunosuppression. May 25th, 2010. Cedars-Sinai Medical Center, Los Angeles, CA.
32. Vo. A. Invited Lecture --Renal Grand Rounds: Management of Highly-HLA Sensitized Patients Awaiting Kidney Transplantation. November 9, 2010. Cedars-Sinai Medical Center, Los Angeles, CA.
33. Vo. A. Invited Lecture-- SICU Teaching Conference: Immunosuppression and the Transplant Patient. January 18, 2011. Cedars-Sinai Medical Center, Los Angeles, CA.
34. Vo. A. Invited Lecture-- Continuing Education for CSMC Department of Pharmacy: Transplant Immunosuppression & Drug Level Monitoring for Post-Kidney Transplant Recipients. April 11, 2011. Cedars-Sinai Medical Center, Los Angeles, CA.
35. Vo, A. Invited Lecture – Nursing Continuing Education: Chemo as Immune Agents. March 28, 2011. Cedars-Sinai Medical Center, Los Angeles, CA.
36. Vo. A. Invited Lecture –ATC 2011 Meeting: Desensitization Protocols in Transplant, ACPE Program. Presented to Transplant Pharmacists. May 1, 2011. Philadelphia, PA.
- Page 43 - Updated –5/26/17 37. Vo, A. Invited Lecture – Nursing Continuing Education: Immunosuppression in Kidney Transplant. November 30, 2011. Cedars-Sinai Medical Center, Los Angeles, CA.
38. Vo, A. Invited Lecture – Nursing Continuing Education: Velcade & Other Chemo Drugs for Immunosuppression. November 30, 2011. Cedars-Sinai Medical Center, Los Angeles, CA.
39. Vo. A. Invited Lecture –ASHP 2011 Meeting: Desensitization Protocols in Transplant, ACPE Program. Presented to Clinical Pharmacists. December 4, 2011. New Orleans, LA.
40. Vo, A. Invited Lecture – CSMC & West LA VA Nephrology Fellows: Immunosuppression in Solid Organ Transplant. February 2012. VA, Los Angeles, CA.
41. Vo, A. Invited Lecture -- CSMC Kidney Transplant Symposium 2012: Currently Relevant Desensitization Protocol -- Outcomes & Economic Impact. March 2012. Palos Verdes, CA.
42. Vo, A. Invited Lecture -- ASTS Transplant Fellowship Core Curriculum: Options for Immunosuppression in Transplant Recipients. January 22, 2013. Cedars-Sinai Medical Center, Los Angeles, CA.
43. Vo, A. Invited Lecture –City of Hope Pharmacy Staff: Immunosuppression in Solid Organ Transplant. February 6, 2013. City of Hope, CA.
44. Vo, A. Invited Lecture – SICU Surgical Teaching Conference: Immunosuppression & The Transplant Patient. March 5, 2013. Cedars-Sinai Medical Center, Los Angeles, CA.
45. Vo, A. Invited Lecture -- Nursing Continuing Education: Transplant Immunosuppression in Kidney Transplant Recipients: A Review. March 11, 2013. Cedars-Sinai Medical Center, Los Angeles, CA.
46. Vo, A. Invited Lecture -- NKF Spring 2013: Therapeutic Options for the Sensitized Patient. April 2013. Orlando, FL.
47. Vo, A. Invited Lecture – AST-ISHLT Joint Symposium at the ISHLT Annual Meeting 2013: Desensitization Therapies in Patients Awaiting Kidney Transplantation. April 2013. Montreal, Canada.
48. Vo, A. Invited Lecture – CSMC Medicine Grand Rounds: Therapeutic Options for the Sensitized Patient. May 3, 2013. Cedars-Sinai Medical Center, Los Angeles, CA.
49. Vo, A. Invited Lecture – CSMC Pulmonary Grand Rounds: Immunosuppression & Antibody Mediated Injury: Implications In Lung Transplant. October 2, 2013. Cedars-Sinai Medical Center, Los Angeles, CA.
50. Vo, A. Invited Lecture – ASHP Midyear Clinical Meeting 2013: Immunoglobulin- Related Tolerability Issues and Adverse Reactions. December 8, 2013. Orlando, FL. - Page 44 - Updated –5/26/17 51. Vo, A. Invited Lecture – SICU Teaching Conference: Immunosuppression & The Transplant Patients. December 12, 2013. Cedars-Sinai Medical Center, Los Angeles, CA.
52. Vo, A. Invited Lecture -- ASTS Transplant Fellowship Core Curriculum: Immunosuppression & Rejections: Prevention & Treatment. January 28, 2014. Cedars-Sinai Medical Center, Los Angeles, CA.
53. Vo, A. Invited Lecture – CSMC & West LA VA Nephrology Fellows: Immunosuppression & Rejections: Prevention & Treatment. January 31, 2014. VA, Los Angeles, CA.
54. Vo, A. Invited Lecture – Benefits, Efficacy, Cost Effectiveness & Infectious Complications in Transplant Patients Desensitized with IVIG and Anti –CD20 Therapy. April 4, 2014. 7th International IG Conference 2014, Interlaken, Switzerland.
55. Vo, A. Invited Lecture – Economics of Desensitization. October 3, 2014. Desensitization and Transplant Antibodies Course (DATA), Orlando, FL.
56. Vo, A. Invited Lecture -- ASTS Transplant Fellowship Core Curriculum: Immunosuppression in Transplant Recipients & Management of HLA Sensitized Patients. January 27, 2015. Cedars-Sinai Medical Center, Los Angeles, CA.
57. Vo, A. Invited Lecture – Pulmonary Grand Rounds: Advancements in Transplantation: Desensitization & Novel Approaches to Improve Outcomes. April 17, 2015. Cedars-Sinai Medical Center, Los Angeles, CA.
58. Vo, A. Invited Lecture – Nephrology Fellowship Core Course. Immunosuppressants and Novel Therapeutics in Kidney Transplant: A Review. January 22, 2016. VA, Los Angeles, CA.
59. Vo, A. Invited Lecture – ASTS Transplant Fellowship Core Curriculum: Pharmacology & Immunosuppressants: A Review. February 23, 2016. VA, Los Angeles, CA.
60. Vo, A. Invited Lecture. In-service for 1st year Nephrology Fellows and Transplant Fellow: Immunosuppression in Kidney Transplant: A Review. July 15, 2016. CSMC.
61. Vo, A. Invited Lecture – ASTS Transplant Fellowship Core Curriculum: Immunosuppression in Kidney Transplant: A Review. February 8, 2017. CSMC, Los Angeles, CA.
62. Vo, A. Invited Lecture – Nephrology Fellowship Core Course. Immunosuppressants and Role of DSAs in Kidney Transplant. February 24, 2017. VA, Los Angeles, CA.
63. Vo, A. Invited Lecture –Surgical Intensive Care Unit. Immunosuppressants and Role of DSAs in Kidney Transplant. March 14, 2017. CSMC, Los Angeles, CA.
- Page 45 - Updated –5/26/17 64. Vo, A. Invited Lecture -- CSMC Kidney Transplant Symposium 2017: Novel Therapeutic Agents Targeting Antibody-Mediated Pathology. May 2017. Palos Verdes, CA.
- Page 46 - Updated –5/26/17